US20120107824A1

US20120107824A1 - mPCR Methods for Analyzing Repeat Sequences

Info

Publication number: US20120107824A1
Application number: US13/284,328
Authority: US
Inventors: Gary J. Latham; Liangjing Chen; Andrew Hadd; Sachin Sah; Ru Cao
Original assignee: Asuragen Inc
Current assignee: Asuragen Inc
Priority date: 2010-10-29
Filing date: 2011-10-28
Publication date: 2012-05-03
Also published as: CN103282517A; JP6081366B2; AU2011320359A1; IL225833A0; CN106868107A; US9777330B2; CN103282517B; AU2011320359B2; JP2013540452A; WO2012058633A1; EP2633073B1; BR112013010585A2; KR101911966B1; BR112013010585B1; KR20140049960A; ZA201303478B; EP2633073A1

Abstract

Methods are provided for determining the methylation status of GC-rich templates. The methods include use of GC reference standards that allow simultaneous characterization of methylation status and CGG repeat length. The methods are useful for detecting genotypes associated with GC-rich repeats, including Fragile X Syndrome.

Description

This application claims the benefit of U.S. Provisional Application No. 61/408,367, filed Oct. 29, 2010, which is incorporated by reference herein in its entirety.
Work described in this application was partially funded by the Federal government under Grants No. R43HD060450 and R44HD060450 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. Accordingly, the Federal government may have certain rights in this invention.
This invention is in the field of nucleic acid analysis, particularly relating to methods for determining the methylation status of GC-rich templates and products. In addition, the invention relates to GC reference standards that may be used according to the methods described herein.
In certain embodiments, the methods described herein are used to determine the methylation status of a GC-rich locus. In some circumstances, expansion of GC-rich regions is associated with various disease states. An example of a locus associated with the expansion of CGG repeats is the 5′ untranslated region (UTR) of the Fragile X Mental Retardation-1 gene (FMR1) on the X chromosome. Expansions in this region to greater than 200 CGG repeats are associated with hypermethylation of the FMR1 gene and are referred to as “full mutation” alleles. These alleles are associated with the loss of FMR1 protein production, and the disorder Fragile X Syndrome (FXS). FXS may include mental retardation, autism, premature ovarian failure, and other cognitive and behavioral conditions. (J. Mol. Diag. 10(6): 496-501 (2008)).
Methods for determining the methylation status of GC-rich templates, and of FMR1, include Southern blot (SB) analysis and polymerase chain reaction (PCR) strategies. SB analysis provides a crude measure of the size of triplet repeat regions and an assessment of methylation. A methylation-sensitive enzyme, which does not cleave methylated sites, may be used to distinguish between methylated and unmethylated alleles. However, the determination of methylation status by SB analysis is limited to alleles that are well resolved by gel electrophoresis. SB analysis is also limited by the amount of genomic DNA (gDNA) material that is required and a tedious workflow that is incompatible with high throughput procedures. (Genet. Med. 7(8): 584-587 (2005)).
PCR strategies may provide greater accuracy in determining the size of the triplet repeat regions. However, limitations in the amplification of long GC-rich sequences, including full mutation alleles of the FMR1 5′ UTR, have restricted the quantification of repeat regions. Optimizations to the PCR of FMR1, for example, have been attempted, and include modifications to conventional PCR assay conditions. (See Genome Res. 6(7): 633-8, (1996); J. Mol. Diagn. 8: 544-550, (2006); and Am J Med Genet. 51(4): 527-34, (1994)). More recently, a PCR technique has been developed that permits reliable amplification of over 200 CGG repeats. See US Application No. 2010/0209970, incorporated herein by reference in its entirety. However, PCR alone does not permit the characterization of methylation status of a GC-rich template.
Several strategies combine PCR with other methods for assessing methylation. Most of the methods have exploited the resistance of 5-methylcytosine to bisulfite conversion to reveal methylation status. However, for FMR1, for example, bisulfite-based methylation PCR methods have been practically limited to evaluations of male samples only, due to the mixed methylation states that confound interpretations of female samples, and/or the methods have demonstrated limited utility for expanded alleles. (See Hum. Mutation 14: 71-79, (1999); Clin. Chem. 52: 1492-1500, (2006); J. Med. Genet. 41: 1-8, (2004); and Hum. Genet. 108: 450-458, (2001)). Alternatives to bisulfite treatment, such as the use of methylation-sensitive restriction enzymes, have been reported, however, the analysis of female samples remains problematic. (J. Mol. Diag. 10(6): 496-501, (2008)).
To date, no single approach other than SB has demonstrated accurate methylation assessments for expanded alleles in both male and female samples. Therefore, a need remains for a rapid, accurate, assay with a simple workflow that can be used to characterize the methylation and repeat status of a GC-rich locus.
The methods described herein relate to a PCR-based technology that can detect and resolve methylation status across the spectrum of GC-rich repeat lengths in both male and female samples. The overall workflow is amenable to routine testing and high throughput screening applications, and provides the foundation for comprehensive FMR1 analyses without the requirement for SB analysis.
In one embodiment, the methods relate to characterizing a FMR locus in a DNA sample comprising the steps of:
a) contacting a first portion of the sample with a methylation-sensitive DNase;
b) adding a GC reference standard to the sample, wherein the reference standard has at least 75% GC-richness;
c) subjecting the first portion and a second portion of the sample, each containing the GC reference standard, to a DNA amplification reaction, wherein the amplified DNA in each portion is labeled with a different label; and
d) analyzing the amplified DNA from the first and the second portion of the sample, thereby characterizing the methylation status of the FMR locus.
In certain embodiments, step (d) comprises capillary electrophoresis (CE). In additional embodiments, the amplified DNA from the first and the second portion are analyzed in a single CE run. In some methods, the GC reference standard is devoid of recognition sites for the methylation-sensitive DNase. In certain methods, the GC reference standard has a CE migration time that does not overlap with a naturally occurring FMR allele. For example, the GC reference standard may have a relative retention time of less than about 20, about 24 to 27, or greater than about 32 CGG repeats. In additional examples, the GC reference standard has a relative retention time of about 175 to about 225 CGG repeats. In some embodiments, the GC reference standard is added to the sample after contacting the first portion with the DNase.
In other embodiments, the amplification reaction is capable of amplifying at least 200 CGG repeats. Certain amplification reactions comprise a dNTP mixture with a GC/AT ratio greater than 1, such as from about 2.5 to about 10. In certain methods, the FMR locus is FMR1. In some methods the methylation-sensitive DNase is chosen from Hpa II, Eag I, or Nru I.
In further embodiments, the second portion of the sample is contacted with a control enzyme. In some instances, the control enzyme is chosen from EcoRI and Sau3A1. In other instances, the control enzyme is chosen from EcoRI, DpnI, NaeI, and HindIII-HF.
Certain embodiments described herein relate to a method of analyzing a human DNA sample comprising the steps of:
a) contacting a first portion of the sample with a methylation-sensitive DNase;
b) adding a GC reference standard to the sample, wherein the reference standard has at least 75% GC-richness;
c) subjecting the first portion and a second portion of the sample to a DNA amplification reaction, wherein the amplified DNA in each portion is labeled with a different label; and
d) analyzing the amplified DNA from the first and the second portion of the sample, thereby detecting a genotype associated with FXS, Fragile X-associated tremor ataxia syndrome, and/or Fragile X-associated primary ovarian insufficiency.
Certain embodiments described herein relate to a GC reference standard comprising a nucleic acid sequence of the formula: 5′-A-B-C-3′, wherein A is a sequence comprising at least 10 consecutive nucleotides of SEQ ID NO: 40 wherein A is capable of specifically hybridizing to a genomic FMR1 5′ untranslated region; C is a sequence comprising at least 10 consecutive nucleotides of SEQ ID NO: 41 wherein C is capable of specifically hybridizing to a genomic FMR1 5′ untranslated region; and B is a sequence having at least 75% GC-richness, and is between X−300 and X+10 nucleotides in length. X is the sum of a) the number of nucleotides between the 3′ end of A and the last nucleotide of SEQ ID NO: 40; and b) the number of nucleotides from the first nucleotide of SEQ ID NO: 41 to the 5′ end of C.
In certain embodiments, B is between 150 and 200 nucleotides in length. In additional embodiments, B has at least 90% GC-richness. In further embodiments, B has at least 94% GC-richness. In one embodiment, A comprises GCGCTCAGCTCCGTTTCGGT (SEQ ID NO: 17). In an additional embodiment, C comprises AGTGCGGGGCTCCAATGGCG (SEQ ID NO: 39).
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 provides an example of the procedural workflow for determining methylation status of GC-rich alleles in which HpaII is used as the methylation-sensitive DNase.

FIG. 2 shows an example of a GC reference standard designed to migrate at a relative retention time that does not overlap with a naturally-occurring FMR1 GC-rich locus.

FIG. 3A shows electropherograms of methylated DNA standards with known fractions of FMR1 methylation. Each trace includes the profile of the DNA standard in the background of a full mutation allele from cell line DNA (−645 CGG).

FIG. 3B shows a plot of the linear fit of known input methylated DNA standards versus detected percent methylation. Quantification of the background, fully methylated 645 CGG allele is superimposed (Mean=104±5%).

FIGS. 4A-D show capillary electropherograms of 4 cell line samples subject to mPCR, with matching SB data.

FIGS. 5A-D show capillary electropherograms of 4 representative clinical samples with full mutation alleles, with matching SB data.

FIGS. 6A-D show capillary electropherograms of 4 representative clinical female permutation samples, with matching SB data.

FIG. 7 shows titration of a 1% mass fraction of a clinical full mutation allele in a background of a normal 31 CGG allele in both the HEX and FAM channels.

FIG. 8 shows titration of a 10% mass fraction of a fully methylated full mutation sample (#08) in the background of a 90% mass fraction of a fully unmethylated full mutation sample (#125).

FIG. 9 shows a comparison of clinical samples analyzed using EagI or HpaII.

FIG. 10 shows an alternative procedural workflow for determining methylation status of GC-rich alleles and a digestion control and CGG DNA control (CGG reference standard) are added to the sample before dividing the sample into two portions and conducting digestion reactions, in one of which HpaII is used as the methylation-sensitive DNase.

FIGS. 11A-D show representative capillary electropherograms of 4 cell line DNA samples subjected to an mPCR assay according to the alternative workflow of FIG. 10, with comparative data from a parallel Southern blot analysis. Provided in boxes beneath the peaks are raw retention time (first row), peak identity (second row), and peak intensity (third row). Peak intensities are expressed as maximum fluorescence (peak height) in arbitrary fluorescence units. Peak identity abbreviations are as follows: DIG.C=digestion control; REF=GC reference standard; FM=full mutation allele; PM=premutation allele; NOR=normal allele.

FIGS. 12A-G show representative capillary electropherograms of 7 clinical specimens subjected to an mPCR assay according to the alternative workflow of FIG. 10, with comparative data from a parallel Southern blot analysis. Boxes beneath the peaks provide information as in FIGS. 11A-D.

EXEMPLARY EMBODIMENTS

In certain aspects, the invention provides methods for characterizing the methylation status of GC-rich nucleic acid templates. In exemplary embodiments, the methods involve treatment with a methylation-sensitive DNase in combination with PCR in the presence of a GC reference standard. The methods described herein may be referred to as “mPCR” methods.
To assist in understanding the present invention, certain terms are first defined. Additional definitions are provided throughout the application.
The use of the word “a”, “an” or “the” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”
“GC/AT Ratio” means the ratio of the concentration of the sum of dCTP, dGTP, and all nucleotide analogs thereof, to the concentration of the sum of dATP, dTTP, dUTP, and all nucleotide analogs thereof, in a given solution or mixture.
“dNTP” stands for deoxynucleotide triphosphate and refers to dATP, dCTP, dGTP, dTTP, dUTP, and analogs thereof.
“Nucleotide analogs” are molecules or ions comprising a base moiety other than the natural bases adenine (A), cytosine (C), guanine (G), thymine (T), or uracil (U), a sugar moiety identical or similar to deoxyribose, and at least one phosphate or multiple phosphate (e.g., diphosphate or triphosphate) moiety. The nucleotide analog is an analog of a specific nucleotide, in particular dATP, dCTP, dGTP, dTTP, or dUTP, when it comprises a triphosphate and a sugar moiety, the structure and configuration of both of which are suitable for incorporation into a nucleic acid double helix by a polymerase, and a base whose base pairing properties in a nucleic acid double helix and loci of incorporation by DNA polymerases in a nucleic acid double helix are most similar to one of the five previously listed nucleotides, with the exception that analogs of dTTP will generally also be analogs of dUTP and vice versa.
“GC-richness” is the fraction or percentage of total nucleobase residues in a nucleic acid that are guanine residues, cytosine residues, or analogs thereof. For example, a 100 nt nucleic acid that contains exactly 30 cytosines, exactly 30 guanines, exactly one cytosine analog, and exactly one guanine analog has a GC-richness of 62%. In some embodiments, a GC-rich template may contain at least 51, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 99.5% guanine residues, cytosine residues, or analogs thereof.

I. METHODS OF CHARACTERIZING METHYLATION STATUS

In certain embodiments, the invention relates to methods of characterizing the methylation status of a GC-rich nucleic acid template. Generally, the methods include the steps of contacting a first portion of a sample with a methylation-sensitive DNase, adding a GC reference standard to the sample, subjecting the first portion and a second portion of the sample to a nucleic acid amplification reaction, and analyzing the amplified nucleic acids from the first and the second portions of the sample. In some embodiments, the first portion and second portion are differentially labeled.
In further embodiments, the second portion is contacted with a control enzyme prior to amplification, where the control enzyme does not cleave the amplified sequence. The control enzyme can be chosen from, for example, EcoRI, DpnI, NaeI, and HindIII-HF. Additional possibilities include Sau3A, NheI, TfiI, ApaLI, MluCI, NcoI, ScaI, StuI, XmnI and Hpy16611. In some embodiments, the control enzyme is chosen from a restriction endonuclease with a recognition site that does not occur within the region that is amplified by the DNA amplification reaction. In some embodiments, the control enzyme is chosen from enzymes that exhibit little if any nonspecific cleavage (star activity) at non-target sites within the region that is amplified by the DNA amplification reaction, such as less than 20%, 15%, 10%, 5%, 3%, or 1% cleavage of non-target sites within the region that is amplified by the DNA amplification reaction. The extent of cleavage is expressed in terms of the fraction of molecules undergoing at least one cleavage event within the region that is amplified by the DNA amplification reaction.
In additional embodiments, the analysis of the first and second portion are performed in a single assay.
FIGS. 1 and 10 show diagrams outlining exemplary assays according to the methods of the invention.
In certain embodiments, the methods described herein may be used to detect genotypes associated with FXS, Fragile X-associated tremor ataxia syndrome, and Fragile X-associated primary ovarian insufficiency. Genetic loci associated with these conditions are known in the art and include without limitation FMR1, FMR2, the 5′ UTR of FMR1, the 5′ UTR of FMR2, the CGG repeats within the 5′ UTR of FMR1, and the CCG repeats within the 5′ UTR of FMR2. As used herein, the term “FMR locus” refers to an FMR1 locus or an FMR2 locus. In an additional embodiment, the methods may be used to detect genotypes associated with GC-rich trinucleotide repeat disorders, such as FXS, Fragile X-associated tremor ataxia syndrome, and Fragile X-associated primary ovarian insufficiency, myotonic dystrophy, Huntington's disease, spinobulbar muscular atrophy, Dentatorubropallidoluysian atrophy, and/or spinocerebellar ataxia. Genetic loci associated with these conditions are known in the art and include without limitation FMR1, FMR2, DMPK, ZNF9, HTT, AR, ATN1, ATXN1-3, ATXN7, ATXN10, CACNA1A, SCA8, PPP2R2B, and TBP. See, e.g., Nat. Genet. 1996 May; 13(1):105-8; Nat. Genet. 1996 May; 13(1):109-13. Hyperexpansion and/or hypermethylation of the GC-rich regions at these loci are associated with the diseases.
A. GC Reference Standard
In some aspects, the invention relates to a GC reference standard that can be used according to the methods described herein. The GC reference standards of the methods described herein are external reference standards, and are designed to be co-amplified with the FMR loci. In some embodiments, the GC reference standards can be used to assess the number of CGG repeats present in a genetic locus, such as a GC-rich locus present near the FMR1 gene. In exemplary embodiments, the GC reference standard is designed such that it has a desired relative retention time by CE.
As used herein, the term “relative retention time” refers to the amount of time it takes for an product amplified from the GC reference standard to migrate through a capillary in CE, compared to the migration time of other amplified products of a given length and/or GC-richness. In certain embodiments, the relative retention time of a GC reference standard is compared to sequences containing known numbers of CGG repeats. In some instances, the GC reference standard is used to determine the number of CGG repeats in a FMR1 locus from a human subject. In certain embodiments, the relative retention time of a GC reference standard is compared to a genetic locus using the same primers for amplification. In some embodiments, the GC reference standard has a relative retention time in a CE assay such that it does not overlap with a naturally occurring FMR1 allele. For example, in an assay to determine the methylation status and number of CGG repeats in an FMR1 locus, a GC reference standard that has a relative retention time of zero CGG repeats compared to naturally-occurring genomic alleles containing CGG repeats can be included. Another embodiment includes a GC reference standard that has a relative retention time of about 40 CGG repeats. In additional embodiments, the GC reference standard has a relative retention time of less than about 20, about 24 to about 27, or greater than about 32 CGG repeats compared to genomic samples.
Exemplary GC reference standards contain sequences having the formula:
5′-A-B-C-3′
wherein A and C represent sequences recognized by forward and reverse PCR primers, and B is a GC-rich sequence. Generally, the GC reference standard has a GC-richness of at least 50, 60, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent. Sequence A may be chosen from a genomic sequence upstream of a GC-rich or CGG repeat region, and sequence C may be chosen from a genomic sequence downstream of such a region. During the amplification reaction, these sequences or their complements can be used as primer recognition sites, such that the reference standard is amplified using the same primers as the target sequence.
In certain embodiments, sequences A and C are chosen from the FMR1 5′-UTR upstream and downstream of the GC-rich region, respectively. The sequences of A and C, or their complements, may be used as primers for the amplification reaction. Examples of sequence A include: CGG TGG AGG GCC GCC TCT GAG C (SEQ ID NO: 1), CAG GCG CTC AGC TCC GTT TCG GTT T (SEQ ID NO: 2), CAG TCA GGC GCT CAG CTC CGT TTC G (SEQ ID NO: 3), TCC GGT GGA GGG CCG CCT CTG AGC (SEQ ID NO: 4), GGT TCG GCC TCA GTC AGG CGC TCA GCT CCG TTT CG (SEQ ID NO: 5), GGG TTC GGC CTC AGT CAG GCG CTC AGC TCC GTT TCG (SEQ ID NO: 6), GCG GGC CGG GGG TTC GGC CTC AGT CA (SEQ ID NO: 7), CAG CGG GCC GGG GGT TCG GCC TCA G (SEQ ID NO: 8), GCA GCG GGC CGG GGG TTC GGC CTC A (SEQ ID NO: 9), GGG CCG GGG GTT CGG CCT CAG TCA G (SEQ ID NO: 10), GGG GTT CGG CCT CAG TCA GGC GCT CA (SEQ ID NO: 11), GGG GTT CGG CCT CAG TCA GGC GCT CAG (SEQ ID NO: 12), GGC GCT CAG CTC CGT TTC GGT TTC ACT TCC (SEQ ID NO: 13), TCA GGC GCT CAG CTC CGT TTC GGT TTC A (SEQ ID NO: 14), CAC TIC CGG TGG AGG GCC GCC TCT GA (SEQ ID NO: 15), TTC CGG TGG AGG GCC GCC TCT GAG C (SEQ ID NO: 16), and GCG CTC AGC TCC GTT TCG GT (SEQ ID NO: 17).
Examples of sequence C include: CAC CTC TCG GGG GCG GGC TCC (SEQ ID NO: 18), ACC TCT CGG GGG CGG GCT CCC (SEQ ID NO: 19), ATG GAG GAG CTG GTG GTG GAA GTG CG (SEQ ID NO: 20), CAC CTC TCG GGG GCG GGC TCC CG (SEQ ID NO: 21), ACC TCT CGG GGG CGG GCT CCC GG (SEQ ID NO: 22), CAC CTC TCG GGG GCG GGC TCC CGG (SEQ ID NO: 23), CAC CTC TCG GGG GCG GGC TCC CGG CG (SEQ ID NO: 24), ACC TCT CGG GGG CGG GCT CCC GGC GC (SEQ ID NO: 25), ACC TCT CGG GGG CGG GCT CCC GGC G (SEQ ID NO: 26), TGG TGG AAG TGC GGG GCT CCA ATG GCG C (SEQ ID NO: 27), TGG AAG TGC GGG GCT CCA ATG GCG C (SEQ ID NO: 28), GGA AGT GCG GGG CTC CM TGG CGC T (SEQ ID NO: 29), GTG GM GTG CGG GGC TCC MT GGC G (SEQ ID NO: 30), TGG TGG TGG AAG TGC GGG GCT CCA A (SEQ ID NO: 31), GAG GAG CTG GTG GTG GM GTG CGG GGC T (SEQ ID NO: 32), AGG AGC TGG TGG TGG AAG TGC GGG GCT C (SEQ ID NO: 33), CTG GTG GTG GAA GTG CGG GGC TCC MT G (SEQ ID NO: 34), AGA TGG AGG AGC TGG TGG TGG MG TGC GGG (SEQ ID NO: 35), GGA AGT GCG GGG CTC CM TGG CGC TTT CTA (SEQ ID NO: 36), GGA AGT GCG GGG CTC CAA TGG CGC TT (SEQ ID NO: 37), TGG AGG AGC TGG TGG TGG AAG TGC G (SEQ ID NO: 38), and AGT GCG GGG CTC CM TGG CG (SEQ ID NO: 39).
SEQ ID NOs 40 and 41 show the FMR1 sequences upstream and downstream of the CGG repeat region. In certain embodiments, sequence A comprises at least 10 nucleotides from SEQ ID NO: 40, and sequence C comprises at least 10 nucleotides from SEQ ID NO: 41.
Sequence B is a GC-rich sequence, and may have a length such that the reference standard has a particular relative retention time in a CE analysis. The retention time can be measured in relation to known standards with defined lengths and GC character. For example, the length of sequence B may be chosen so the reference standard has a relative retention time of less than about 20, about 24 to about 27, or greater than about 32 CGG repeats compared to genomic samples. The length of sequence B may be chosen so the reference standard has a relative retention time of less than or about zero CGG. In certain examples, the reference standard has a relative retention time of about −100, −90, −80, −70, −60, −50, −40, −30, −20, −10 or zero CGG repeats. In some embodiments, the GC reference standard has a relative retention time of less than or equal to 3, 2, 1, zero, −1, −2, −3, −4, −5, −10, −15, or −20 CGG repeats. The relative retention time of the reference standard can be chosen such that it does not overlap with either the primer peak or a naturally occurring FMR1 allele. The relative retention time of the GC reference standard can also be chosen such that it does not overlap with the digestion control (discussed below), when one is used.
The GC reference standard can have a negative relative retention time, for example, when the reference standard has less flanking sequence surrounding the GC-rich region than the products amplified from a genomic sample. Thus, a GC reference standard may actually contain a positive number of CGG repeats but have a retention time equivalent to a hypothetical genomic sample with a negative number of CGG repeats due to a difference in flanking sequence content.
In some embodiments, the length of B is from X−300 to X+10 nucleotides in length, where X is the sum of:
a) the number of nucleotides between the 3′-end of sequence A and the beginning of the GC-rich region; and b) the number of nucleotides between the end of the GC-rich region and the 5′ end of sequence C.
In some embodiments, B comprises or consists of the sequence CGGCGGCGGaGGCGGCGGCGGCGGCGGCGGCGGCGGCGGtGGaGGCGGCGGC GGCGGCGGCGGCGGCGGCGGCGGCGGCGGaGGCGGCGGCGGCGGCGGCGGC GGCGGCGGCGGCGGCGGaGGCGGCGGCGG (SEQ ID NO: 48). In some embodiments, B comprises at least 50, 75, 100, or 125 nucleotides of SEQ ID NO: 48. In some embodiments, B comprises or consists of the sequence CGGCGGCGGaGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGaGGCGGCGG CGGCGGCGGCGGCGGCGGCGGCGGCGGCGGaGGCGGCGGCGGCGGCGGCGG CGGCGGCGGCGGCGGCGGaGGCGGCGGCGG (SEQ ID NO: 49). In some embodiments, B comprises at least 50, 75, 100, or 125 nucleotides of SEQ ID NO: 49. In some embodiments, B comprises or consists of a sequence that hybridizes under stringent conditions with SEQ ID NO:48 or SEQ ID NO: 49.
An example of stringent hybridization conditions is hybridization at 42° C. in a solution comprising 50% formamide, 5×SSC (where 1×SSC is 150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA, followed by washing at 65° C. in a solution comprising 0.1×SSC.
FIG. 2 shows an example of a GC reference standard that has a relative retention time that does not overlap with naturally-occurring sequences from an FMR1 GC-rich locus.
In certain embodiments, the GC reference standard is contained within a plasmid or other vector. The plasmid or other vector may be linearized, for example by digestion with a restriction enzyme, or left intact. In one embodiment, the plasmid is pBR322. When the GC reference standard is added to a sample or a portion of a sample as part of a larger DNA molecule, such as a plasmid, the amplification reaction does not necessarily amplify all parts of the larger DNA molecule (e.g., sequences that may not be amplified can include a plasmid origin of replication, antibiotic resistance marker, intervening noncoding sequences, etc.), and for purposes of this disclosure, such non-amplified sequences in a molecule comprising the GC reference standard are not considered in determining the relative retention time or GC-richness of the GC reference standard.
The GC reference standard can be added to a nucleic acid sample before or after treatment with the methylation-sensitive DNase. Adding the GC reference before treatment with the methylation-sensitive DNase can reduce errors that may otherwise result from pipetting the GC reference standard into two portions of the sample, one of which was treated with the methylation-sensitive DNase and one of which was not. That is, when the GC reference is added to the sample before treatment with the methylation-sensitive DNase, it may be added to the sample before dividing the sample into two portions. In embodiments in which the GC reference standard is added to the sample before the methylation-sensitive DNase or control enzyme, the GC reference standard is not cleaved by the DNase, e.g., it may be devoid of recognition sites for the DNase and/or it may be methylated such that it is resistant to cleavage by the methylation-sensitive DNase. When the GC reference standard is added to the sample after treatment of a portion of the sample with the methylation-sensitive DNase, the GC reference standard is added to the first and second portions of the sample. The amount of GC reference standard added to the sample can vary depending on the type of amplification reaction and the extent of amplification (e.g., the number of cycles or the length of isothermal incubation). For example, in some embodiments using PCR as the amplification reaction, about 750 to about 12,000 copies of the GC reference standard can be added for each PCR reaction.
B. Digestion Control
The methods described herein may include the use of a digestion control. The digestion control is designed to be co-amplified with a region in the sample DNA, such as an FMR locus. The digestion control is unmethylated and contains at least one recognition site for the methylation-sensitive DNase, and thus is cleaved upon treatment with the methylation-sensitive DNase. As a result, this control template reports the effectiveness of the digestion by the methylation-sensitive restriction endonuclease.
In some embodiments, the digestion control has a structure and length such that it has a particular relative retention time in a CE analysis. In embodiments in which the amplification reaction comprises PCR, the same primers may be used to amplify the genomic target locus and the digestion control. Fragments of the digestion control resulting from digestion by the methylation-sensitive DNase do not support amplification of the digestion control. In some embodiments, the digestion control has a relative retention time of less than about 20, about 24 to about 27, or greater than about 32 CGG repeats compared to genomic samples. In certain examples, the digestion control has a relative retention time of about −100, −90, −80, −70, −60, −50, −40, −30, −20, −10 or zero CGG repeats. In some embodiments, the digestion control has a relative retention time of less than or equal to 3, 2, 1, zero, −1, −2, −3, −4, −5, −10, −15, or −20 CGG repeats. The relative retention time of the digestion control can be chosen such that it does not overlap with either the primer peak or a naturally occurring FMR1 allele. The relative retention time of the digestion control can also be chosen such that it does not overlap with the GC reference standard.
In certain embodiments, the digestion control is contained within a plasmid or other vector. The plasmid or other vector may be linearized, for example by digestion with a restriction enzyme, or left intact. In one embodiment, the plasmid is pBR322. When the digestion control is added to a sample or a portion of a sample as part of a larger DNA molecule, such as a plasmid, the amplification reaction does not necessarily amplify all parts of the larger DNA molecule (e.g., sequences that may not be amplified can include a plasmid origin of replication, antibiotic resistance marker, intervening noncoding sequences, etc.), and for purposes of this disclosure, such non-amplified sequences in a molecule comprising digestion control are not considered in determining the relative retention time or GC-richness of the digestion control.
In some embodiments, the digestion control comprises or consists of the sequence TCAGGCGCTCAGCTCCGTTTCGGTTTCACGGTGACGGAGGCGCCGCTGCCCGGG GGCGTGCGGCAGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGC GGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGC GGCGGCGGCGGCTGGGCCTCGAGCGCCCGCAGCCCAGGAAGTGGAAGTGCGGG GCTCCAATGGCGCT (SEQ ID NO: 50). The underlined portions are examples of the flanking sequences which can be adjusted to modify the size of the resulting amplicon. In some embodiments, the digestion control comprises or consists of at least 100, 150, 175, 200, or 220 nucleotides of SEQ ID NO: 50. In some embodiments, the digestion control comprises or consists of a sequence that hybridizes under stringent conditions to SEQ ID NO: 50. In some embodiments, the digestion control comprises or consists of a sequence that is a version of SEQ ID NO: 50 modified in that it has a larger or smaller number of CGG repeats, such that the digestion control has a relative retention time as discussed above.
In some embodiments, the relative retention times of the digestion control and the reference standard differ by the equivalent of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more CGG repeats. Template or primer slipping may occur in GC-rich amplification reactions, resulting in products that differ in length by about 1-3 CGG repeats from the original target. Thus, in particular embodiments, the relative retention times of the digestion control and the reference standard differ by the equivalent of 4 or more CGG repeats to minimize signal overlap. In some embodiments, both the digestion control and the reference standard have a relative retention time of less than or equal to 3, 2, 1, zero, −1, −2, −3, −4, −5, −10, or −15 CGG repeats. In some embodiments, the digestion control has the general primary structure described in section I.A above for some embodiments of the GC reference standard, including A, B, and C sequences as described above. When both of the digestion control and GC reference standard comprise A, B, and C sequences as described above, at least one of the A, B, or C segments in the digestion control may differ in length from its counterpart in the GC reference standard, such that the digestion control is of a length that differs by the equivalent of at least 1, 2, 3, 4, 5, or more CGG repeats from the length of the reference standard. The digestion control will still have an appropriate methylation status for digestion by the methylation-sensitive nuclease (which status may be the opposite of the methylation status of the reference standard).
The amount of digestion control added to the sample can vary depending on the type of amplification reaction and the extent of amplification (e.g., the number of cycles or the length of isothermal incubation). For example, in some embodiments using PCR as the amplification reaction, about 750 to about 12,000 copies of the digestion control can be added for each PCR reaction.
C. Methylation-Sensitive Nuclease
The methods described herein may include the use of a methylation-sensitive nuclease. In some instances, the nuclease is a DNase such as a restriction enzyme. The methylation-sensitive nuclease of the methods provided herein differentially cleaves the portion of the FMR locus that is amplified based on its methylation state. A control nuclease does not cleave that portion.
Methylation-sensitive DNases include AatII, Acc65I, AccI, AciI, AclI, AfeI, AgeI, AeI-HF™, AhdI, AleI, ApaI, ApaLI, AscI, AsiSI, AvaI, AvaII, BaeI, BanI, BbvCI, BceAI, BcgI, BfuAI, BfuCI, BgII, BmgBI, BsaAI, BsaBI, BsaHI, BsaI, BsaI-HF™, BseYI, BsiEI, BsiWI, BsII, BsmAI, BsmBI, BsmFI, BspDI, BspEI, BsrBI, BsrFI, BssHII, BssKI, BstAPI, BstBI, BstUI, BstZ17I, BtgZI, Cac8I, ClaI, DraIII, DrdI, EaeI, EagI, EagI-HF™, EarI, EciI, EcoRI, EcoRI-HF™, EcoRV, EcoRV-HF™, FauI, Fnu4HI, FokI, FseI, FspI, HaeII, HgaI, HhaI, HincII, HinfI, HinP1I, HpaI, HpaII, Hpy166II, Hpy188III, Hpy99I, HpyAV, HpyCH4IV, KasI, MboI, MluI, MmeI, MspA1I, MwoI, NaeI, NarI, NciI, NgoMIV, NheI, NheI-HF™, NlaIV, NotI, NotI-HF™, NruI, Nt.BbvCI, Nt.BsmAI, Nt.CviPII, PaeR7I, PhoI, PleI, PmeI, PmII, PshAI, PspOMI, PspXI, PvuI, RsaI, RsrII, SacII, SaII, SaII-HF™, Sau3AI, Sau96I, ScrFI, SfaNI, SfiI, SfoI, SgrAI, SmaI, SnaBI, StyD4I, TfiI, TliI, TseI, TspMI, XhoI, XmaI, or ZraI (New England Biolabs; Nature Protocols 1: 1621-1636 (2006)).
In certain embodiments, the methylation-sensitive DNase is chosen from HpaI, NruI, EagI, BssHII, and HhaI. In certain embodiments, the methylation-sensitive DNase is HpaII.
Recognition sites for selected methylation-sensitive DNases are shown below:


		Methylation
Enzyme	Sequence	Sensitivity

Aatll	GACGT/C	Cleavage blocked

Acc65l	G/GTACC	Cleavage blocked

Accl	GT/MKAC	Cleavage blocked

Acil	CCGC(−3/−1)	Cleavage blocked

Acll	AA/CGTT	Cleavage blocked

Afel	AGC/GCT	Cleavage blocked

Agel	A/CCGGT	Cleavage blocked

Ael-HF ™	A/CCGGT	Cleavage blocked

Ahdl	GACNNN/NNGTC	Cleavage impaired

Alel	CACNN/NNGTG	Cleavage impaired

Apal	GGGCC/C	Cleavage blocked

ApaLl	GGGCC/C	Cleavage blocked

Ascl	GG/CGCGCC	Cleavage blocked

AsiSl	GCGAT/CGC	Cleavage blocked

Aval	C/YCGRG	Cleavage blocked

Avall	G/GWCC	Cleavage blocked

Bael	(10/15)ACNNNNGTAYC	Cleavage blocked
	(12/7)

Banl	G/GYRCC	Cleavage blocked

BbvCl	CCTCAGC(−5/−2)	Cleavage impaired

BceAl	ACGGC(12/14)	Cleavage blocked

Bcgl	(10/12)CGANNNNNNTGC	Cleavage blocked
	(12/10)

BfuAl	ACCTGC(4/8)	Cleavage impaired

BfuCl	/GATC	Cleavage blocked

Bgll	GCCNNNN/NGGC	Cleavage blocked

BmgBl	CACGTC(−3/−3)	Cleavage blocked

BsaAl	YAC/GTR	Cleavage blocked

BsaBl	GATNN/NNATC	Cleavage blocked

BsaHl	GR/CGYC	Cleavage blocked

Bsal	GGTCTC(1/5)	Cleavage blocked

Bsal-HF ™	GGTCTC(1/5)	Cleavage blocked

BseYl	CCCAGC(−5/−1)	Cleavage blocked

BsiEl	CGRY/CG	Cleavage blocked

BsiWl	C/GTACG	Cleavage blocked

Bsll	CCNNNNN/NNGG	Cleavage blocked

BsmAl	GTCTC(1/5)	Cleavage blocked

BsmBl	CGTCTC(1/5)	Cleavage blocked

BsmFl	GGGAC(10/14)	Cleavage blocked

BspDl	AT/CGAT	Cleavage blocked

BspEl	T/CCGGA	Cleavage impaired

BsrBl	CCGCTC(−3/−3)	Cleavage blocked

BsrFl	R/CCGGY	Cleavage blocked

BssHll	G/CGCGC	Cleavage blocked

BssKl	/CCNGG	Cleavage blocked

BstAPl	GCANNNN/NTGC	Cleavage blocked

BstBl	TT/CGAA	Cleavage blocked

BstUl	CG/CG	Cleavage blocked

BstZ17l	GTA/TAC	Cleavage blocked

BtgZl	GCGATG(10/14)	Cleavage impaired

Cac8l	GCN/NGC	Cleavage blocked

Clal	AT/CGAT	Cleavage blocked

Dralll	CACNNN/GTG	Cleavage impaired

Drdl	GACNNNN/NNGTC	Cleavage blocked

Eael	Y/GGCCR	Cleavage blocked

Eagl	C/GGCCG	Cleavage blocked

Eagl-HF ™	C/GGCCG	Cleavage blocked

Earl	CTCTTC(1/4)	Cleavage impaired

Ecil	GGCGGA(11/9)	Cleavage blocked

EcoRl	G/AATTC	Cleavage blocked

EcoRl-HF ™	G/AATTC	Cleavage blocked

EcoRV	GAT/ATC	Cleavage impaired

EcoRV-HF ™	GAT/ATC	Cleavage impaired

Faul	CCCGC(4/6)	Cleavage blocked

Fnu4Hl	GC/NGC	Cleavage blocked

Fokl	GGATG(9/13)	Cleavage impaired

Fsel	GGCCGG/CC	Cleavage blocked

Fspl	TGC/GCA	Cleavage blocked

Haell	RGCGC/Y	Cleavage blocked

Hgal	GACGC(5/10)	Cleavage blocked

Hhal	GCG/C	Cleavage blocked

Hincll	GTY/RAC	Cleavage blocked

Hinfl	G/ANTC	Cleavage blocked

HinP1l	G/CGC	Cleavage blocked

Hpal	GTT/AAC	Cleavage blocked

Hpall	C/CGG	Cleavage blocked

Hpy166ll	GTN/NAC	Cleavage blocked

Hpy188lll	TC/NNGA	Cleavage blocked

Hpy99l	CGWCG/	Cleavage blocked

HpyAV	CCTTC(6/5)	Cleavage impaired

HpyCH4lV	A/CGT	Cleavage blocked

Kasl	G/GCGCC	Cleavage blocked

Mbol	/GATC	Cleavage impaired

Mlul	A/CGCGT	Cleavage blocked

Mmel	TCCRAC(20/18)	Cleavage blocked

MspA1l	CMG/CKG	Cleavage blocked

Mwol	GCNNNNN/NNGC	Cleavage blocked

Nael	GCC/GGC	Cleavage blocked

Narl	GG/CGCC	Cleavage blocked

Ncil	CC/SGG	Cleavage impaired

NgoMlV	G/CCGGC	Cleavage blocked

Nhel	G/CTAGC	Cleavage blocked

Nhel-HF ™	G/CTAGC	Cleavage blocked

NlalV	GGN/NCC	Cleavage blocked

Notl	GC/GGCCGC	Cleavage blocked

Notl-HF ™	GC/GGCCGC	Cleavage blocked

Nrul	TCG/CGA	Cleavage blocked

Nt.BbvCl	CCTCAGC(−5/−7)	Cleavage blocked

Nt.BsmAl	GTCTC(1/−5)	Cleavage blocked

Nt.CviPll	(0/−1)CCD	Cleavage blocked

PaeR7l	C/TCGAG	Cleavage blocked

Phol	GG/CC	Cleavage impaired

Plel	GAGTC(4/5)	Cleavage blocked

Pmel	GTTT/AAAC	Cleavage blocked

Pmll	CAC/GTG	Cleavage blocked

PshAl	GACNN/NNGTC	Cleavage blocked

PspOMl	G/GGCCC	Cleavage blocked

PspXl	VC/TCGAGB	Cleavage impaired

Pvul	CGAT/CG	Cleavage blocked

Rsal	GT/AC	Cleavage blocked

Rsrll	CG/GWCCG	Cleavage blocked

Sacll	CCGC/GG	Cleavage blocked

Sall	G/TCGAC	Cleavage blocked

Sall-HF ™	G/TCGAC	Cleavage blocked

Sau3Al	/GATC	Cleavage blocked

Sau96l	G/GNCC	Cleavage blocked

ScrFl	CC/NGG	Cleavage blocked

SfaNl	GCATC(5/9)	Cleavage impaired

Sfil	GGCCNNNN/NGGCC	Cleavage blocked

Sfol	GGC/GCC	Cleavage blocked

SgrAl	CR/CCGGYG	Cleavage blocked

Smal	CCC/GGG	Cleavage blocked

SnaBl	TAC/GTA	Cleavage blocked

StyD4l	/CCNGG	Cleavage impaired

Tfil	G/AWTC	Cleavage blocked

Tlil	C/TCGAG	Cleavage impaired

Tsel	G/CWGC	Cleavage blocked

TspMl	C/CCGGG	Cleavage blocked

Xhol	C/TCGAG	Cleavage impaired

Xmal	C/CCGGG	Cleavage impaired

Zral	GAC/GTC	Cleavage blocked

In certain embodiments, a first portion of a sample is treated with a methylation-sensitive nuclease, while a second portion is treated with a control nuclease. The control nuclease may be a restriction enzyme that does not cleave the amplified locus. The control nuclease may be a non-methylation-sensitive nuclease. Many restriction enzymes and their specificities are well known in the art. Examples of control nucleases that can be used in the described methods include HindIII-HF, DpnI, NaeI, EcoRI, or Sau3A1, among others. Control nucleases are discussed in more detail above in the initial portion of section I.
D. Amplification Methods
The methods of the invention also include nucleic acid amplification. Many methods exist for amplifying nucleic acid sequences including reverse transcription, polymerase chain reaction (PCR), real-time PCR (RT-PCR), nucleic acid sequence-base amplification (NASBA), ligase chain reaction, multiplex ligatable probe amplification, invader technology (Third Wave), rolling circle amplification, in vitro transcription, strand displacement amplification, transcription-mediated amplification (TMA), RNA (Eberwine) amplification, loop-mediated isothermal amplification, and other methods that are known to persons skilled in the art. In some embodiments, the methods further comprise processing concatenated amplification products generated by an amplification reaction such as rolling circle amplification or loop-mediated isothermal amplification, e.g., by endonucleolytic cleavage of a recognition site present in the amplification template or incorporated primer, in order to provide non-concatenated amplification products for downstream analysis.
A typical PCR reaction includes multiple amplification steps, or cycles that selectively amplify target nucleic acid species. A typical PCR reaction includes three steps: a denaturing step in which a target nucleic acid is denatures; an annealing step in which a set of PCR primers (forward and reverse primers) anneal to complementary DNA strands; and an elongation step in which a thermostable DNA polymerase elongates the primers. By repeating these steps multiple times, a DNA fragment is amplified to produce an amplicon, corresponding to the target DNA sequence. Typical PCR reactions include 20 or more cycles of denaturation, annealing, and elongation. In many cases, the annealing and elongation steps can be performed concurrently, in which case the cycle contains only two steps.
In certain methods, a set of primers is used for each target sequence. In some embodiments, a single set of primers can amplify both the GC reference standard and the target nucleic acid. In certain embodiments, the lengths of the primers depends on many factors, including, but not limited to, the desired hybridization temperature between the primers, the target nucleic acid sequence, and the complexity of the different target nucleic acid sequences to be amplified. In certain embodiments, a primer is about 15 to about 35 nucleotides in length. In other embodiments, a primer is equal to or fewer than 15, 20, 25, 30 or 35 nucleotides in length. In additional embodiments, a primer is greater than 35 nucleotides in length. In some embodiments, the set of primers includes one primer that hybridizes to SEQ ID NO: 40, and a second that hybridizes to SEQ ID NO: 41. A primer may include at least 10 contiguous nucleotides depicted in SEQ ID NO: 40, or a primer may includes at least 10 contiguous nucleotides complementary to the depicted strand of SEQ ID NO: 41.
In certain embodiments, the methods include PCR reactions capable of amplifying at least 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000 or more CGG repeats. Exemplary methods capable of amplifying large GC-rich templates are described, for example, in US Publication No. 2010/0209970, which is incorporated herein by reference in its entirety.
The PCR reactions may include providing dNTPs in a GC/AT ratio greater than one and at a total dNTP concentration conducive to synthesis of DNA using GC-rich templates. The GC/AT ratio may be about 1.1, 1.2, 1.4, 1.6, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, or higher. The GC/AT ratio may be between 1.1 and 20, 1.1 and 15, 1.1 and 10, 1.1 and 8, 1.1 and 7, 1.1 and 6, 1.1 and 5, 1.2 and 25, 1.4 and 25, 1.6 and 25, 2 and 25, 3 and 25, 4 and 25, 5 and 25, 2 and 15, 2.5 and 10, or 4 and 10. The total dNTP concentration may be about 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.2, 1.5, 2, or 3 mM. The dNTP concentration may be between 0.4 and 3 mM, 0.5 and 3 mM, 0.6 and 3 mM, 0.7 and 3 mM, 0.8 and 3 mM, 0.9 and 3 mM, 1 and 3 mM, 0.4 and 2 mM, 0.4 and 1.5 mM, 0.4 and 1.2 mM, 0.4 and 1 mM, 0.4 and 0.9 mM, 0.4 and 0.8 mM, 0.4 and 0.7 mM, 0.5 and 2 mM, 0.5 and 1 mM, or 0.6 and 0.9 mM.
The DNA polymerase used in a PCR reaction may comprise a wild-type, modified, thermophilic, chimeric, engineered, and/or a mixture of more than one polymerase. The DNA polymerase may comprise Exact Polymerase (5 PRIME GmbH), AccuSure™ DNA Polymerase (Bioline), Phusion™ AccuPrime™ Pfx (Invitrogen), Platinum Taq DNA Polymerase High Fidelity (Invitrogen), Phire™ Hot Start DNA Polymerase (New England Biolabs), Phusion^aHot Start High-Fidelity DNA Polymerase (New England Biolabs), JumpStart™ REDTaq™ DNA Polymerase (Sigma-Aldrich), PfuUltra™ Hotstart DNA Polymerase (Stratagene), PfuTurbo® Cx Hotstart DNA Polymerase (Stratagene), PrimeSTAR™ HS DNA Polymerase (Takara), Extensor Hi-Fidelity PCR Enzyme (ABgene), ACCUZYME™ DNA Polymerase (Bioline), SAHARA™ DNA Polymerase (Bioline), VELOCITY DNA Polymerase (Bioline), GeneChoice® AccuPOL™ DNA Polymerase (GeneChoice, Inc.), GeneChoice® UniPOL™ DNA Polymerase (GeneChoice, Inc.), Elongase Enzyme Mix (Invitrogen), Pfx50™ DNA Polymerase (Invitrogen), Phusion DNA Polymerase (New England Biolabs), KOD HiFi DNA Polymerase (Novagen), KOD XL DNA Polymerase (Novagen), Expand 20 kb PLUS Thermostable DNA polymerase mixture (Roche Applied Science), Expand High Fidelity PLUS Thermostable DNA polymerase mixture (Roche Applied Science), Expand High Fidelity Thermostable DNA polymerase mixture (Roche Applied Science), Expand Long Template Thermostable DNA polymerase mixture (Roche Applied Science), Easy-ATM High-Fidelity PCR Cloning Enzyme (Stratagene), EXL™ DNA Polymerase (Stratagene), Herculase® Enhanced DNA Polymerase (Stratagene), Herculase® II Fusion DNA Polymerase (Stratagene), Kapa LongRange™ DNA Polymerase (Kapa Biosystems), Kapa HiFi™ DNA Polymerase (Kapa Biosystems), Kapa2G™ Robust DNA Polymerase (Kapa Biosystems), Kapa2G™ Robust HotStart DNA Polymerase (Kapa Biosystems), Kapa2G™ Fast DNA Polymerase (Kapa Biosystems), Kapa2G™ Fast HotStart DNA Polymerase (Kapa Biosystems), LA TAQ DNA Polymerase (Takara), Optimase DNA Polymerase (Transgenomic, Inc.), Exo-Pfu DNA Polymerase (Stratagene), HotMaster Taq DNA Polymerase (5 PRIME GmbH), HotTaq DNA Polymerase (Abnova Corporation), AmpliTaq Gold® DNA Polymerase (Applied Biosystems), Bst DNA Polymerase Lg Frag (New England Biolabs), MasterAmp™ Tfl DNA Polymerase (EPICENTRE Biotechnologies), Red Hot DNA Polymerase (ABgene), Thermoprime Plus DNA Polymerase (ABgene), Taq-red DNA Polymerase (AppliChem GmbH), BIO-X-ACT™ Long DNA Polymerase (Bioline), BIO-X-ACT™ Short DNA Polymerase (Bioline), Bioline HybriPol™ DNA Polymerase (Bioline), BioTherm Taq DNA Polymerase (eEnzyme LLC), EU-Taq DNA Polymerase (eEnzyme LLC), Synergy Taq DNA Polymerase (eEnzyme LLC), GeneChoice® RedPOL™ DNA Polymerase (GeneChoice, Inc.), AccuPrime™ GC-Rich DNA Polymerase (Invitrogen), PyroPhage® 3173 DNA Polymerase, Exo Minus (Lucigen), 9 Degrees North (Modified) DNA Polymerase (New England Biolabs), Therminator DNA Polymerase (New England Biolabs), Pwo DNA Polymerase (Roche Applied Science), Paq5000™ DNA Polymerase (Stratagene), YieldAce™ DNA Polymerase (Stratagene), e2TAK™ DNA Polymerase (Takara), or naturally occurring DNA polymerases from P. kodakaraensis, P. furiosus, T. gorgonarius, T. zilligii, T. litoralis “Vent™”, P. GB-D “Deep Vent”, T. 9N-7, T. aggregans, T. barossii, T. fumicolans, T. celer, Pyrococcus sp. strain ST700, T. pacificus, P. abysii, T. profundus, T. siculi, T. hydrothermalis, Thermococcus sp. strain GE8, T. thioreducens, P. horikoshii or T. onnurineus NA 1, Thermococcus sp. 9° N-7, Thermococcus sp. GI-J, Thermococcus sp. MAR-13, Thermococcus sp. GB-C, Thermococcus sp. GI-H, Thermus aquaticus, Thermus thermophilus, Thermus caldophilus, Thermus filiformis, Thermus flavus, Thermotoga maritima, Bacillus stearothermophilus, or Bacillus caldotenax, for example.
In exemplary embodiments, the amplified nucleic acids are labeled during the amplification reaction. In certain instances, the portion of the sample treated with methylation-sensitive DNase is labeled with a first label, and the control portion of the sample is labeled with a second label. In some embodiments, each label is detectable by CE.
Labels include, but are not limited to: light-emitting, light-scattering, and light-absorbing compounds which generate or quench a detectable fluorescent, chemiluminescent, or bioluminescent signal (see, e.g., Kricka, L., Nonisotopic DNA Probe Techniquies, Academic Press, San Diego (1992) and Garman A., Non-Radioactive Labeling, Academic Press (1997).). Fluorescent reporter dyes useful as labels include, but are not limited to, fluoresceins (see, e.g., U.S. Pat. Nos. 5,188,934, 6,008,379, and 6,020,481), rhodamines (see, e.g., U.S. Pat. Nos. 5,366,860, 5,847,162, 5,936,087, 6,051,719, and 6,191,278), benzophenoxazines (see, e.g., U.S. Pat. No. 6,140,500), energy-transfer fluorescent dyes, comprising pairs of donors and acceptors (see, e.g., U.S. Pat. Nos. 5,863,727; 5,800,996; and 5,945,526), and cyanines (see, e.g., WO 9745539). Examples of fluorescein dyes include, but are not limited to, 6-carboxyfluorescein; 2,4′,1,4,-tetrachlorofluorescein; and 2′,4′,5′,7′,1,4-hexachlorofluorescein. Example cyanine dyes include the WellRed® infrared dyes D1, D2, D3 or D4. Additional labels may be derived from lissamine, phycoerythrin, Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, Fluor X (Amersham), Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein Isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, SYPRO, TAMRA, Tetramethylrhodamine, and/or Texas Red, as well as any other fluorescent moiety capable of generating a detectable and distinct dye signal from another label. Examples of fluorescein dyes include, but are not limited to, 6-carboxyfluorescein; 2′,4′,1,4,-tetrachlorofluorescein; and 2′,4′,5′,7′,1,4-hexachlorofluorescein. In certain aspects, the fluorescent label is selected from SYBR-Green, 6-carboxyfluorescein (“FAM”), TET, NED, ROX, VIC™, or JOE that are compatible with CE analysis. For example, in certain embodiments, labels are different fluorophores capable of emitting light at different, spectrally-resolvable wavelengths (e.g., 4-differently colored fluorophores); certain such labeled probes are known in the art and described above, and in U.S. Pat. No. 6,140,054. A dual labeled fluorescent probe that includes a reporter fluorophore and a quencher fluorophore is used in some embodiments. Other examples may include Freedom® dyes that are commercially available surrogates for common dyes. It will be appreciated that pairs of fluorophores are chosen that have distinct emission spectra so that they can be easily distinguished.
In still a further aspect, labels are hybridization-stabilizing moieties which serve to enhance, stabilize, or influence hybridization of duplexes, e.g., intercalators and intercalating dyes (including, but not limited to, ethidium bromide and SYBR-Green), minor-groove binders, and cross-linking functional groups (see, e.g., Blackburn et al., eds. “DNA and RNA Structure” in Nucleic Acids in Chemistry and Biology (1996)).
It will be appreciated that in circumstances using two or more labels in a single assay, labels that have distinct emission spectra are chosen such that they can be easily distinguished. In some examples, FAM and HEX labels can be used to label a first portion and a second portion of a sample. In additional embodiments, FAM or HEX may be used with NED or ROX labels, among others, in the methods described herein.
E. Analysis Methods
In some embodiments, the amplified nucleic acids are analyzed to determine methylation status. In exemplary embodiments, the analysis method is capillary electrophoresis (CE) using instruments familiar to those in the art such as the ABI 3100, 3130, 3730, or 3500 models. Other implementations include any instrument capable of electrophoretic sizing of DNA and multicolor resolution. For example, the Beckman Vidiera or SEQ6000 capillary electrophoresis systems for the detection of WellRed infrared dyes (D1, D2, D3 and D4) may also be used or the Li-Cor instrument incorporating IRDyes. Other methods that may be used include microfluidic CE systems such as the Agilent 2100 Bioanalyzer and similar platforms, mass spectrometry, agarose gel electrophoresis followed by scan densitometry, and analysis of radiolabeled products using phosphorImager or scan densitometry of autoradiographs. In additional embodiments, the amplified nucleic acids from the first and the second portions of the sample are analyzed in a single CE assay.
Certain analysis methods such as CE allow for simultaneous characterization of methylation status and the number of CGG repeats present in a template. In certain embodiments, CE analysis is performed using POP-4,5,6, or 7 liquid polymer with a 36 or 50 cm column. In one embodiment, the liquid polymer is POP-7.
In certain embodiments, a percentage methylation can be calculated. Intensities of peaks observed in CE electropherograms, phosphorimager scans, densitometric scans, mass spectra, or other forms of data can be determined according to suitable methods known in the art, for example, methods such as peak height, area under the curve (integration), or curve fitting. Peak intensity values from corresponding peaks from the portions of the sample treated as the control and subjected to digestion by the methylation-sensitive DNase can then be compared; the peak intensities can be normalized using the GC reference standard. For example, normalization can be performed by expressing each observed peak intensity as a ratio to the peak intensity observed for the GC reference standard in the same portion of the sample.
In other embodiments, methylation status can be characterized as non-methylated or methylated. In still further embodiments, methylation status can be categorized as non-methylated, partially methylated, or fully methylated.

II. SAMPLES

The methods provided herein relate to characterization of the methylation status of a nucleic acid template in a sample. In certain embodiments, a nucleic acid sample is obtained from a human. For example, the sample may be a patient sample. A “patient sample” is any biological specimen from a patient. The term includes, but is not limited to, biological fluids such as blood, serum, plasma, urine, cerebrospinal fluid, tears, saliva, lymph, dialysis fluid, lavage fluid, semen, and other liquid samples, as well as cells and tissues of biological origin. Cells and tissues may include buccal cells, mouthwash collections, or skin cells, including hair follicles. The term also includes cells isolated from a human or cells derived therefrom, including cells in culture, cell supernatants, and cell lysates. It further includes organ or tissue culture-derived fluids, tissue biopsy samples, tumor biopsy samples, stool samples, and fluids extracted from physiological tissues, as well as cells dissociated from solid tissues, tissue sections, and cell lysates. It may also include post-mortem solid tissue samples, such as those from brain. In some embodiments, the sample contains less than about 80, 100, 150, 200, 500, or 1,000 ng of DNA.
In some instances, the sample includes genomic DNA. The DNA may be separated from other non-DNA components of the sample before being subjected to the methods of the invention. Many methods of DNA separation and purification are known in the art.
A sample may contain a DNA template. In certain methods described herein, a DNA template may be the target of synthesis in a reaction catalyzed by a DNA polymerase. The GC-richness of the DNA template may be greater than or equal to 75, 80, 85, 90, 95, 96, 97, 98, 99, or 99.5% C and G residues. The DNA template may comprise di-, tri-, or tetranucleotide repeats comprising C and G residues. The DNA template may comprise a sequence within or near a disease-associated locus. The DNA template may comprise at least part of the 5′ UTR of the FMR1 or FMR2 gene. The DNA template may comprise CGG repeats of the 5′ UTR of the FMR1 or CCG repeats in the 5′ UTR of the FMR2 gene. The size of the DNA template may be about 50, 100, 200, 300, 500, or 700 bp, or 1, 1.5, 2, 2.5, 3, 4, 5, 7, or 10 kb. The size of the DNA template may be between 50 bp and 10 kb, 100 bp and 10 kb, 200 bp and 10 kb, 300 bp and 10 kb, 500 bp and 10 kb, 700 bp and 10 kb, 1 kb and 10 kb, 1.5 bp and 10 kb, 2 bp and 10 kb, 3 bp and 10 kb, 50 bp and 7 kb, 50 bp and 5 kb, 50 bp and 4 kb, 50 bp and 3 kb, 50 bp and 2 kb, 50 bp and 1.5 kb, 100 bp and 7 kb, 200 bp and 5 kb, or 300 bp and 4 kb.

III. EXAMPLES

The following examples illustrate various embodiments of the invention and are not intended to limit the scope of the invention.

Example 1

Workflow for Characterizing Methylation Status

FIG. 1 shows an example of the mPCR methodology described herein. Sample DNA is treated with a reaction mix containing a methylation-sensitive DNase such as HpaII i, which degrades the unmethylated templates but retains the methylated alleles, or with a control mix without the methylation-sensitive enzyme. Each portion of the sample DNA is subject to PCR in the presence of an external GC reference standard. The PCR is further capable of amplifying alleles with over 200 CGG repeats. The primers for the HpaII portion and the control portion have different labels (e.g., FAM and HEX). The PCR products are then pooled and analyzed by capillary electrophoresis. A loss in amplicon signal on CE indicates digestion and the lack of methylation at either HpaII site, whereas the retention of signal indicated methylation of the corresponding allele. The fraction of methylation by allele is determined from the ratio of amplicon yield for a given allele that was digested with HpaII relative to that for the corresponding undigested allele. This ratio is normalized to the signal of the external GC reference standard.

Example 2

Experimental Procedures

A. Clinical and Cell Line DNA Samples
gDNA from blood samples were obtained from subjects seen at the M.I.N.D. Institute Clinic, following Institutional Review Board approval (Filipovic-Sadic et al., Clin Chem 2010; 56:399-408). Cell line DNA samples were obtained from the Coriell Cell Repositories (CCR, Coriell Institute for Medical Research, Camden, N.J.). Clinical and cell line DNA samples were diluted to 20 ng/μL in 10 mM Tris, 0.5 mM EDTA, pH 8.8 prior to PCR.
B. FMR1 Methylation PCR
Two aliquots of 40 ng gDNA from each sample are prepared for methylation assessment using AmplideX™ Methylation PCR reagents (Asuragen, Inc., Austin, Tex.). Restriction enzymes are from New England Biolabs. One aliquot of DNA is mixed with digestion buffer and methylation-sensitive enzyme (HpaII unless otherwise noted), and the second aliquot with digestion buffer and a control enzyme such as Sau3AI or EcoRI. The restriction enzymes are present in the reaction mixture in a final concentration of 0.15 U/μl. Examples of the final concentration of buffer components in each reaction are shown in Table 1 (not including reagent contributions from the enzyme storage buffer).

TABLE 1

Exemplary Reaction Conditions

	Reagent	Concentration

Digestion Mix A

MgCl

₂	10 mM
	Bis-Tris-Propane-HCl, pH 7.0	10 mM
	Dithiothreitol
	1 mM

Digestion Mix B

MgCl

₂	10 mM
	Tris-HCl	50 mM
	NaCl
	100 mM

Digestion Mix C

	MgCl₂	7.5 mM
	TrisHCl, pH 7.5	10 mM
	BSA
	100 μg/ml

The HpaII and control reactions are incubated at 37° C. for two hours in sealed 96 well plates. Separate PCR mastermixes of methylation PCR reagents are prepared for either the HpaII-treated (FAM primers) or non HpaII-control (HEX primers) products, and are dispensed directly into the restriction enzyme digestion or the control digestion mixture. Each mastermix contains mPCR AMP Buffer (Asuragen, Catalog No. 145152), GC-rich Polymerase Mix (Asuragen, Catalog No. 145153), deionized water, and mPCR primers (Fwd: 5′TCAGGCGCTCAGCTCCGTTTCGGTTTCA-3′ (SEQ ID NO: 42); Rev: 5′-FAM- or HEX-AAGCGCCATTGGAGCCCCGCACTTCC (SEQ ID NO: 43)) (Filipovic-Sadic, 2010). Each mastermix also contains an external GC reference standard (−3000-12,000 copies/PCR reaction, depending on the number of PCR cycles).
The final PCR buffer/reagent conditions are the same as in the AmplideX™ FMR1 kit (Asuragen, Catalog No. 49402; US Application No. 2010/0209970), except for additional 0.67 mM MgCl₂, 2.66 mM Bis-Tris-Propane, pH 7.0, and 0.266 mM DTT (for Digestion Mix A samples); additional 10 mM TrisHCl, pH 7.5, and 20 mM NaCl (for Digestion Mix B samples); or additional 2.66 mM TrisHCl, pH 7.5, and 26.6 μg/ml BSA (for Digestion Mix C samples) carried over from the digestion buffer.
Certain reactions may use a GC reference standard that has a relative retention time of 40 CGG (SEQ ID NO: 44; “40-CGG-Control”), which is constructed by inserting 30 nucleotides of a non-human DNA sequence to a plasmid containing 30 CGG repeats. During the PCR step, the reference standard is amplified from the plasmid. Additional examples include a reference standard that has a relative retention time of zero CGG (Asuragen, Catalog No. 49441; SEQ ID NO: 45; “zero-CGG-Control”), also contained within a plasmid. Non-plasmid controls with alternate migration times are also used, as noted.
The samples are PCR amplified with an initial heat denature step of 95° C. for 5 minutes, followed by 25 cycles of 97° C. for 35 sec, 62° C. for 35 sec and 72° C. for 4 min, and 72° C. for 10 minutes. Amplicons are prepared for CE analysis, or stored at −15 to −30° C.
The sequence of the FMR1 amplicon, along with indication of the two HpaII sites that are probed is depicted as follows:
5′-X-(CGG repeat region)-Y-3′
wherein X is

(SEQ ID NO: 46)

TCAGGCGCTCAGCTCCGTTTCGGTTTCACTT

TGGAGGGCCGCCTCTG

AGCGGGCGGCGGGCCGACGGCGAGCGCGGGCGGCGGCGGTGACGGAGG

CGCCGCTGCCAGGGGGCGTGCGGCAGCG;

and Y is

(SEQ ID NO: 47)

CTGGGCCTCGAGCGCCCGCAGCCCACCTCTCGGGGGCGGGCTC

CG

CTAGCAGGGCTGAAGAGAAGATGGAGGAGCTGGTGGTGGAAGTGCGGGG

CTCCAATGGCGCTT-3′.

In SEQ ID NOs: 46 and 47, the underlined regions designate sequences bound by the forward and reverse primers, and the italicized and underlined CCGG sequences indicate the two HpaII sites.
C. Capillary Electrophoresis (CE)
A 3130×/Genetic Analyzer (Applied Biosystems Inc., ABI, Foster City, Calif.) is used for the experiments, except where noted. A total of 2 μL of unpurified PCR products (1 μL each from the HEX-labeled products and FAM-labeled products) are mixed with 11 μL of HI-D1 Formamide® (ABI) and 2 μL of ROX 1000 Size Ladder (Asuragen), heat denatured at 95° C. for 2 minutes and transferred to the CE system for analysis. Except where noted, injections follow the standard fragment sizing conditions (36 cm, POP7) using an injection of 2.5 kV for 20 s and a 40 min run at 15 kV. An ABI 3500×L CE (50 cm, POP7) is used where noted. Due to resolution limitations of the POP7 polymer, all FMR1 amplicons with >250 CGG repeats have similar mobilities on CE.
D. Data Analysis
Electropherograms are analyzed using GeneMapper 4.0 (4.1 for 3500×L data) or PeakScanner V1.0 software (ABI). The conversion of base pair size to number of CGG repeats is determined by linear regression to control amplicons produced from templates with 20, 29, 31, 54 and 119 CGG repeats (Filipovic-Sadic, 2010). Peak sizes for each peak are converted to CGG repeat length using (Size_i230.3/2.975).
Results of CGG repeat length and percent methylation for each detected allele are tabulated in MS Excel. The percent methylation, % M_i, is calculated as a ratio of peak heights between the digested (Peak_i,FAM) and undigested sample (Peak_i,HEX) normalized to the GC reference standard amplicon peak height (CTRL_HEXor CTRL_FAM) as shown in Equation 1:
$\begin{matrix} % M_{i} (height) = (\frac{{CTRL}_{HEX}}{{CTRL}_{FAM}}) \frac{{Peak}_{i, FAM}}{{Peak}_{i, HEX}} & (1) \end{matrix}$
Methylation values that are about 100% or nominally exceed 100% are scored as fully methylated. Such values typically observed within the range of variation of the assay for well represented alleles, as noted below, but are sometimes exaggerated (e.g., 120 to 137%) in methylation assessments of low abundance alleles (e.g., inputs of only 1% mass fraction of a clinical full mutation sample) when the allele-specific signal is near the lower range of detection of the CE instrument and thus quantitatively less reliable relative to the signal of the GC reference standard peak.
E. Southern Blot Analysis
SB analysis of the 80 clinical samples is performed as described in Tassone et al., J Mol Diagn 2008; 10:43-9. Cell line DNA is prepared for SB using EcoRI and EagI (NEB). SB images are assessed categorically (unmethylated, partially methylated and fully methylated alleles) and the percent of methylation in each sample determined as described in Tassone, 2008.

Example 3

Accuracy and Reproducibility of mPCR with Methylated DNA Standards and Samples

To assess the accuracy of the two-color mPCR workflow, a set of 8 defined analytical standards containing 30 CGG repeats and known methylation fractions were developed. Methylated and unmethylated DNA controls were prepared from PCR products of a 30 CGG repeat allele that was cloned into pBR322 following standard procedures (Sambrook J, Fritsch E F, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, N.Y.: CSHL Press, 1989). The 30 CGG standard was methylated with Hpa II methyltransferase (New England Biolabs, NEB, Ipswich, Mass.) and linearized with HindIII (NEB).
Various proportions of the methylated or unmethylated 30 CGG standards were mixed from 0-100% and diluted to 1.5×10⁴copies/A in 20 ng/A of 645 CGG cell line DNA (NA04025, CCR). Cell line DNA samples were obtained from the Coriell Cell Repositories (CCR, Coriell Institute for Medical Research, Camden, N.J.). Each sample was subject to HpaII digestion in Digestion Mix A (Sau3A1 in Digestion Mix A for control reaction), 25 cycles of PCR in the presence of the 40-CGG-Control, and CE as described in Example 2.
A series of electropherograms highlighting the proportional change in signal in the FAM-channel for the 30 CGG standard are shown in FIG. 3A. As the percent methylation increased, the signal for the 30 CGG standard increased relative to the peaks for 40-CGG-control and the admixed 645 CGG full mutation allele. The change in peak height was normalized to the 40-CGG-Control peak height and compared to the normalized ratio in the HEX channel (Eq. 1). A linear relationship (R²=0.998) was observed between the known methylation fraction and the fraction empirically recovered following mPCR, as performed by two operators over three different run days (FIG. 3B), with input methylation indicated on the x-axis, and measured methylation indicated on the y-axis. Methylation of the 645 CGG allele was determined to be quantitative (104±5%) for each of the evaluated standards (FIG. 3B).
The reproducibility of mPCR was further assessed across 8 replicates of 2 normal alleles (30 and 32 CGG from a female clinical sample) and 2 full mutation alleles (550 CGG and 940 CGG) on 2 CE instrument platforms (an ABI 3130×/and 3500×L). Methylation fractions, standard deviations, coefficients of variation (CV), and 95% confidence intervals (CI) are presented in Table 2.

TABLE 2

mPCR assessments of methylation across two CE platforms for normal
and full mutation alleles.

		Allele	Average
Platform	Sample	(CGG)	(%)	Stdev (%)	CV	95% CI

3130xl

AS10017

	30	74	5.3	7%	70.4-77.7
	AS10017	32	25	2.0	8%	23.4-26.2
	NA07862	~550	101	10.0	10%	94.5-108.4
	NA09237	~940	97	15.7	16%	86.5-108.3
3500xL	AS10017		30	76	5.7	8%	71.8-79.7
	AS10017	32	27	2.1	8%	25.9-28.8
	NA07862	~550	101	8.0	8%	95.7-106.8
	NA09237	~940	97	12.0	12%	88.6-105.3

The calculated mPCR methylation fraction yielded a CV=7-8% for the normal alleles, and a CV=8-16% for the full mutation alleles across the two different platforms. In addition, mPCR results were reproducible across 2 different operators (CV=7%) using 8 cell line samples, including 4 full mutation samples. Measurements of percent methylation that sometimes exceeded 100% were a consequence of the stated variation of the method, and such samples were tabulated as fully methylated for comparison purposes with SB analysis. As demonstrated in the examples below, the mPCR method yielded results for clinical samples that were at least as good as SB analysis.

Example 4

mPCR Assessments of Cell Line DNA and Comparisons with SB Analysis

mPCR was evaluated with 8 commercially available cell line DNA templates that included normal, premutation and full mutation alleles from both male and female samples. Samples were subject to HpaII digestion in Digestion Mix A (Sau3A1 in Digestion Mix A for control reaction), 25 cycles of PCR in the presence of the 40-CGG-Control, and CE as described in Example 2. Results for allele size and methylation status from mPCR and SB analyses are summarized in Table 3.

TABLE 3

Comparison of mPCR and SB analyses for 8 cell line DNA samples.
Samples in bold are shown in FIG. 4.

SB Analysis

mPCR

Sample Information

Categorical

mPCR

			Coriell Catolog	Estimated	Methylation	CE
			Repeat Length	Size	(full, partial,	Repeat	Methylation
Sample ID	Genotype	Sex	(CGG)	(~CGG)	or non)	length	% on CE

NA06892	PM	M	93 (80-85)	~110	Non	90	2%
NA09145	FM	M	full	660~990	Full	>250	109%
NA06852	FM	M	>200	395	Full	>250	108%
NA04025	FM	M		645	795	Full	>250	113%
NA09237	FM	M	931-940	1062	Full	>250	109%
NA20241	PM	F		29/93-110	Normal	Partial	29	24%
				103-130	Partial	88	83%
						111	83%
						116	0%
NA06896	PM	F		23/95-140	Normal	Partial	23	21%
				148-201	Partial	112	69%
						136	96%
						153	0%
						175	0%
						>250	0%
NA07537	FM	F		28/336	Normal	Partial	29	8%
	FM			329	Full	>250	100%

Electropherograms of 4 samples with matching SB data are shown in FIGS. 4A-D. In each figure, the top panel shows the portion of the sample not treated with HpaII, and the bottom panel shows the digested sample. The sample ID from Table 3 is shown in each figure, along with the repeat length. Repeat lengths in FIG. 4 are labeled using the Coriell designations for >250 CGG, and using the results of PCR when <250 CGG. Each figure also includes methylation percentage determined by mPCR. The peak labeled “Ctrl” indicates the 40-CGG-control.
In each case, the mPCR results were qualitatively consistent with the corresponding SB data. For example, as shown in FIG. 4A, the male premutation allele (NA06892, 90 CGG) presented 2% methylation by mPCR, consistent with the presence of a product that was detected only in the unmethylated region of the SB. Skewed X-inactivation (8% methylation) of a female normal allele (NA07537, FIG. 4C), in combination with a fully methylated full mutation allele, was also concordant with SB analysis, and previously published data (Zhou et al., Clin Chem 52:1492-1500 (2006)).
mPCR provided more detailed interpretations of allele-specific methylation states in complex samples up to −250 CGG in length. For example, a mosaic female sample (NA06896, “23/95-140” according to CCR) was detected with primary peaks of 23, 112, 136 CGG and 4 additional low abundance peaks of 153, 175, 196, and 219 CGG (FIG. 4D). The 23 CGG and 112 CGG peaks were partially methylated, the 136 CGG peak was fully methylated, and the peaks between 153 and 219 were completely unmethylated.
These results were qualitatively similar to the results from SB analysis. SB revealed a mostly unmethylated 23 CGG allele, a broad set of expanded unmethylated alleles (<5.2 kb), and a more defined set of expanded methylated alleles. Importantly, mPCR data revealed individual size mosaic contributions to the unmethylated smear pattern in SB. For example, the SB image was consistent with a partially methylated 112 CGG and unmethylated higher repeat alleles of 153-219 CGG as reported by mPCR.

Example 5

Methylation PCR Assay Performance with Clinical DNA Samples

The FMR1 mPCR assay was evaluated with a set of 80 clinical specimens representing the full range of clinically relevant allele sizes and methylation states, and selected from the same set previously evaluated for allele size (Filipovic-Sadic, 2010). Experiments were performed as described in Example 4. Methylation status was also determined by SB (Tassone, 2008). CGG repeat length, percent methylation and comparison to SB data were tabulated for each clinical sample (Table 4) and summarized (Table 5). In Table 4, alleles detected using mPCR were grouped to match resolution limits of SB. Samples with full mutation alleles are shaded in gray, and those in bold are shown in FIGS. 5 and 6. In each figure, the peak labeled “Ctrl” indicates the 40-CGG-Control.
X-activation (Rousseau et al., J Med Genet 28:830-6 (1991)) is the reciprocal of percent methylation for female normal alleles in normal and full mutation samples. The average X-activation was 0.51 for normal female alleles (n=8) and 0.67 for the normal alleles of female full mutation (n=12) samples, consistent with values reported by de Vries et al (0.50 and 0.71, respectively) (de Vries et al., Am J Hum Genet 58:1025-32 (1996)).

TABLE 4

Comparison of mPCR repeat length and percent methylation
with categorical calls and estimated methylation by SB.

SB Analysis

mPCR

Estimated

		Repeat		X-		meth-
Sample	Sample	length	Meth-	acti-	Categorical	ylation
ID	Call	(CGG)	ylation	vation^a	Call by SB^b	by SB^c

		160 >250	0% 96%		Partial	60%

		20 >250	27% 104%	0.73	Partial Full	30% 100%

		>250	108%		Full	100%

		201 >250	124% 0%		Partial	50%

#11	PM	29 105 108-166	83% 87% 0%		Partial Partial	70% 40%

		218 >250	110% 0%		Partial	80%

		39 >250	50% 83%	0.5	Partial Partial	50% 90%

		29 226	18% 111%	0.82	Partial Full	15% 100%

		>250	102%		Full	100%

		30 214 >250	56% 84% 116%	0.44	Partial Full (Faint) Full	40% >70% 100%

#56	PM	30 84	4% 96%		Non Full		0% 100%

		>250	111%		Full	100%

#58	PM	30 88 89-101	35% 111% 0%		Partial Partial	30% 60%

		30 >250	0% 95%	1.0	Non Full	0% 100%

		>250	100%		Full	100%

#61	PM	20 147 180	11% 127% 102%		Partial Full	10% 100%

		>250	103%		Full	100%

		30 142 155 >250	4% 97% 122% 109%	0.96	Partial Full Full Full	5% 100% 100%

#64	NOR	31	0%		Non		0%
#65	PM	79-85	0%		Non		0%

		186 >250	92% 114%		Full Full		100% 100%

#67	PM	30 92 95-108	24% 125% 0%		Partial Partial	20% 60%

		20 >250	38% 91%	0.62	Partial Full	40% 100%

		30 >250	5% 112%	0.95	Partial Full	5% 100%

		30 >250	28% 110%	0.72	Partial Full	25% 100%

#71	NOR	23	43%	0.57	Partial	50%
		30	57%	0.43
#72 ^d	INT	30	85%		Partial	85%
		53	26%		Partial	30%
		54-55	0%
#73	PM	63	0%		Non		0%
#74	PM	101-117	0%		Non		0%
		118-140	0%
#75 ^d	PM	32	57%		Partial	50%
		90	99%		Partial	50%
		92-101	0%
#76 ^d	PM	32	40%		Partial	30%
		107	111%		Partial	60%
		109-125	0%

		30 >250	40% 107%	0.60	Partial Full	30% 100%

#78	NOR	21	66%		Partial	50%
		30	45%
		31	30%
#79	PM	30	36%		Partial	50%
		60	64%
		61-64	0%
#80	NOR	30	0%		Non		0%
#81	NOR	29	49%	0.51	Partial	40%
		30	37%	0.63
#82	PM	89	0%		Non		0%
#83	PM	34	10%		Non		0%
		79	115%		Partial	90%
		80-86	0%
#84	PM	59	0%		Non		0%
#85	PM	20	23%		Partial	60%
		102	86%		Partial	20%
		103-113	0%
#86	PM	30	76%		Partial	70%
		110	112%		Partial	20%
		112-124	0%

		>250	96%		Full	100%

		>250	82%		Partial	90%

#89	PM	68	0%		Non		0%

		223 >250	70% 80%		Partial	80%

		198 228	100% 0%		Partial	50%

#92	NOR	30	0%		Non		0%
#93	NOR	30	51%	0.49	Partial	50%
		32	42%	0.58

		236 >250	101% 75%		Full Partial	100% 80%

#95 ^d	PM	32	75%		Partial	60%
		70	46%
		71-75	0%
#96	PM	35	45%		Partial	30%
		80	45%		Partial	50%
		81-85	0%
#97	PM	92-96	0%		Non		0%
#98	NOR	23	0%		Non		0%
#99	PM	74-79	0%		Non		0%
		93-100	0%		Non		0%
#100	PM	65-70	0%		Non		0%
#101	PM	143-153	0%		Non		0%
#102	INT	30	38%		Partial	50%
		53	49%

		>250	102%		Full	100%

		>250	96%		Full	100%

#105	PM	29	17%		Partial	10%
		92	100%		Partial	70%
		93-97	0%
#106	PM	38	37%		Partial	40%
		78	80%		Partial	50%
		80-86	0%
#107	PM	80-84	0%		Non		0%
		90-95	0%
#108	PM	23	32%		Partial	35%
		71	63%		Partial	50%
		73-74	0%
#109	PM	30	54%		Partial	50%
		86	90%		Partial	50%
		88-94	0%

		>250	93%		Full	100%

#111	PM	106-110	0%		Non		0%
#112	PM	41	11%		Partial	10%
		112	165%		Partial	85%

		>250	99%		Full	100%

#114	NOR	31	0%		Non		0%
#115	NOR	30, 30	51%	0.49	Partial	50%
#116	NOR	30	46%	0.54	Partial	50%
		31	51%	0.49

		30 >250	44% 104%	0.56	Partial Full	50% 100%

		29 97 130 >250	81% 0% 0% 74%	0.19	Partial Non Non Full (Faint)	90% 0% 0% >50%

		99 >250	0% 101%		Not visible Full	100%

#120	INT	30	53%		Partial	In-
		53	52%		(Faint)	determine
#121	NOR	30, 30	52%	0.48	Partial	50%
#122	NOR	30, 30	51%	0.49	Partial	50%
#123	NOR	30	87%	0.13	Partial	50%
		31	8%	0.92

		>250	106%		Full	100%

		>250	0%^f		Non (faint smear)	In- determine

^aRousseau et al. and de Vries et al.; data available for certain samples only.
^bFull = no evidence of banding <5.4 kb, Partial = evidence of banding in both regions of blot, Non = no evidence of banding >5.4 kb.
^cDerived as a percent estimate of band intensity between methylated and unmethylated separated bands.
^dElectropherogram and SB image shown in FIG. 6.
^eElectropherogram and SB image shown in FIG. 5.
^fLow abundance allele detected at 160 CGG (60% methylated)

TABLE 5

Concordance of mPCR and SB Analysis in Methylation Assessments of
Clinical Samples with ≧55 CGG Repeats.

Methylation
Status of	mPCR

Clinical	Fully	Partially	Un-
Samples	methyl-	methyl-	methyl-
with Alleles	ated	ated	ated

≧55 CGG	PM	FM	PM	FM	PM	FM	Total

SB	Fully	PM	2	0	0	0	26
	methyl-	FM	0	24
	ated

Partially	PM	0	17	0	0	25
methyl-	FM		0	8
ated

Un-	PM	0	0	11	0	12
methyl-	FM			0	1
ated

Total

	26	25	12	63

mPCR results were in agreement with SB analysis, however, mPCR simplified and improved the detection and interpretation of different methylation states relative to SB. Due of the higher resolution of CE, some alleles that were readily distinguished by mPCR were unresolved by SB (such as two permutations of similar size). In these cases, alleles were grouped to match the resolution limits of SB analysis.
The sensitivity of mPCR was addressed through two different experiments. In the first, titration of as little as a 1% mass fraction of a clinical full mutation allele in a background of a normal 31 CGG allele was detectable in both the HEX and FAM channels (FIG. 7). In the second, a 10% mass fraction of a fully methylated full mutation sample (#08) could be identified in the background of a 90% mass fraction of a fully unmethylated full mutation sample (#125) (FIG. 8). The methylation state of both samples was confirmed by SB analysis as shown in Table 4. Thus, consistent with FIG. 3, even a 10% methylation mosaic could be detected using clinical samples.
A. Identification and Resolution of Methylation Status in Full Mutation Alleles.
The electropherograms and matched SB images for representative full mutation samples are shown in FIG. 5. As previously described (Filipovic-Sadic, 2010), the CE configuration used in these experiments limited the differential resolution of amplicons to those with <250 CGG, and thus the amplification products of larger repeat expansions co-migrated, although the overall percentage methylation for the broad category of full mutations was accurately assessed as supported by the data below. For example, in the male full mutation sample #88 (FIG. 5A), the expanded allele was detected primarily in the methylated region of the SB with a faint product (˜10-20% signal) in the unmethylated region. mPCR revealed 82% methylation for this sample, consistent with the SB result. Further, partial methylation for the normal allele, and full methylation for the expanded allele, was observed using SB for female full mutation sample #117 (FIG. 5B). The mPCR results also indicated partial (44%) methylation of the 30 CGG allele, and full (104%) methylation of the expanded allele.
mPCR simplified the identification of methylation status in more complex samples that can be problematic for SB. The male full mutation sample #125 (FIG. 5C) presented a low intensity smear across the unmethylated region (3 to >5 kb range). Using mPCR, the full mutation peak was clearly detected in the HEX but not the FAM channel despite amplification of the 40-CGG-Control. Thus, the full mutation allele was unmethylated. In another example (FIG. 5D), an unusual pattern of size and methylation mosaicism was resolved. By SB analysis, the full mutation allele appeared partially methylated, whereas mPCR revealed two distinct allele sizes with skewed methylation. The predominant full mutation signal was observed in the unmethylated longer template(s), whereas the less abundant template at −200 CGG was fully methylated. Thus, the size mosaicism was more clearly resolved by mPCR, and the methylation pattern was more complex than that indicated by SB.
B. Identification of Novel Skewing Patterns in Female Premutation Alleles that were Masked by SB Analysis
Electropherograms and matched SB images for 4 representative female premutation samples are shown in FIG. 6. The characteristic feature of each sample was the detection of two groups of repeat sizes for the longer allele, namely 53 and 54-56 CGG, 70 and 71-75 CGG, 90 and 92-101 CGG, and 107 and 109-125 CGG (FIGS. 6A-D, respectively). After digestion and amplification with FAM-labeled primers, only the shorter CGG repeat lengths within each mosaic sample were detected. Because the size mosaicism was not observed in the Hpa II-treated FAM channel of characteristic female samples, nor was it observed after the PCR of any of the 11 tested male premutation alleles of comparable repeat length, it appears that this pattern was not an artifact of polymerase “stuttering”. In each case, the more expanded CGG repeats of the premutation allele were completely unmethylated. This same mosaicism and skewed methylation pattern was identified in 84% (16 out of the 19) female premutation samples within the tested cohort. In contrast, the resolution limitations of SB yielded only one detectable premutation band and thus obscured this level of biological detail. In addition, the skewed mosaicism observed was not specific to an analysis of methylated HpaII sites. Specifically, the mPCR analysis was also performed with EagI rather than HpaII. EcoRI in Digestion Mix B was used for the control reaction. The EagI analysis utilized a CGG control migrating at a relative retention time of about −12.8 CGG repeats, and derived from a PCR amplicon instead of plasmid-based 40-CGG-Control. In addition, PCR primers were selected such that EagI recognition sites were present in the amplicon. The same pattern was observed when the template was treated with EagI, rather than HpaII, and analyzed using a modification of the mPCR method that permitted the assessment of EagI methylated sites (FIG. 9; “Ref” refers to the 40-CGG-Control in HpaII samples and −12.8 GCC control in EagI samples).
The mPCR research procedure can support high volume sample analyses, requiring only a single day and approximately 2 hrs of total hands-on time (much of which can be automated) to process up to 48 samples per operator. In addition, mPCR requires an input of only 80 ng of DNA—a 50- to 100-fold reduction compared to SB, and 10-fold reduction compared to bisulfite (Panagopoulos et al., Hum Mutat 14:71-9 (1999); Zhou et al., Clin Chem 52:1492-500 (2006); Dahl et al., Nucleic Acids Res 35:e144 (2007)) or previously reported HpaII-mediated PCR methods (Carrel et al., Am J Med Genet 64:27-30 (1996); Kline et al., Fertil Steril 85:1488-95 (2006); Allen et al., Am J Hum Genet 51:1229-39 (1992)). As a result, alternative sample types to whole blood that share an ectodermal cell lineage with neuronal cells, such as buccal or skin cells, may be amenable to mPCR analysis even if they do not provide sufficient DNA yields for SB.
The mPCR technology evaluated in this study represents a PCR-based methodology that detects and resolves methylation status across the spectrum of CGG repeat lengths in both male and female samples. The overall workflow is amenable to routine testing and high throughput screening applications. The methods provide the foundation for comprehensive FMR1 analyses without the requirement for SB analysis.

Example 6

mPCR with Alternate Methylation-Sensitive Enzymes

To demonstrate the versatility of the mPCR methods, selected clinical samples were analyzed using the enzymes EagI and NruI, as well as HpaII. Experiments were generally performed as described in Example 2, with samples treated with EagI or NruI in Digestion Mix B for 2 hours, and control samples treated with EcoRI in Digestion Mix B for 2 hours. A non-plasmid −12.8 CGG standard was used for EagI experiments, and a non-plasmid −41 CGG standard was used with NruI samples. PCR primers for EagI and NruI experiments were chosen such that the amplicon contained recognition sites for the appropriate enzymes. HpaII experiments were performed as described in Example 4. Table 6 compares the results of these experiments. Results using the various enzymes differentiated non-methylated vs. methylated alleles, as well as non-methylated, partially methylated, and fully methylated alleles.

TABLE 6

Comparison of HpaII, EagI, and NruI results

		Repeat
Sample	Sample	length	Hpa II	EagI	NruI
ID	Call	(CGG)	Methylation	Methylation	Methylation

#
72	INT	30	85%	68%	84%
		53	26%	61%	28%
		54-55	0%	0%	0%
#75	PM	32	57%	45%	63%
		90	99%	66%	101%
		92-101	0%	0%	0%
#76	PM	32	40%	27%	42%
		107	111%	84%	113%
		109-125	0%	0%	0%
#95	PM	32	75%	53%	62%
		70	46%	36%	49%
		71-75	0%	0%	0%
NA06905	PM
	23	0%	3%	8%
		78	78%	79%	109%

Example 7

Methylation PCR Assay Performance Using a “0 CGG” Reference Standard for Assessing Methylation at HpaII Sites

The methylation status of 6 samples from the Coriell Cell Repository was assessed using the zero-CGG-Control that has a relative retention time outside of the range of detection of biological FMR1 alleles. Experiments were performed as described in Example 2, using HpaII or Sau3A1 (control) in Digestion Mix C, and 27 cycles of PCR. As shown in Table 7, the choice of reference standard did not alter the interpretation of the methylation data across the range of methylation status, from 2% methylation to quantitatively methylated. Results were compared to those generated using the 40-CGG-Control as described in Example 4.

TABLE 7

Comparison of FMR1 methylation status using a “40 CGG” and “0 CGG”
reference standard.

% Methylation

Sample			zero-CGG	40-CGG			zero-CGG	40-CGG
File	Allele
1	Size 1	standard	standard	Allele	2	Size 2	standard	standard

NA07862	FM	>200	97%	113%
NA06897	FM	>200	45%	27%
NA04025	FM	>200	99%	99%
NA09237	FM	>200	101%	107%
NA07537	NOR	29	6%	6%	FM	>200	94%	77%
NA20239	NOR	20	4%	2%	PM	198	97%	81%

Example 8

Control Nuclease

The methods described herein can include the use of an endonuclease in the control reaction to cleave the large genomic DNA outside the amplification region of the FMR1 locus, and reduce the size of DNA templates comparable to those in the methylation-sensitive digestion reaction and thus comparably favorable for PCR amplification.
Many restriction enzymes and their specific recognition sites are well characterized. A total of 14 commercially available restriction endonucleases were selected for testing, including Sau3A, EcoRI, NaeI, DpnI, HindIII-HF, NheI, TfiI, ApaLI, MluCI, NcoI, Scat, StuI, XmnI and Hpy16611.
Examples of restriction enzymes that may be used in the method include Sau3A, EcoRI, NaeI, DpnI and HindIII-HF. Sau3A exhibited reduced selectivity with respect to cleavage of non-target sites on the template. EcoRI, NaeI, DpnI and HindIII-HF exhibited a high degree of selectivity, in that little to no cleavage of non-target sites in the template (i.e., the region of the FMR1 locus bounded by SEQ ID NOs: 40 and 41) was observed.

TABLE 8

Comparison of the restriction endonucleases tested
in the control digestion reaction.

		Template
Endonuclease	Recognition Sequence	selectivity

EcoRl	G/AATTC	+++

Sau3A	/GATC	+

Dpnl	GA/TC	+++

Nael	GCC/GGC	+++

Hindlll-HF	A/AGCTT	+++

Example 9

Alternative Workflow for Characterizing Methylation Status

An alternative workflow for characterizing methylation status is shown in FIG. 10. In this workflow, a genomic DNA sample is premixed together with digestion control and the GC reference standard (referred to in the figure as CGG DNA control). Each portion of DNA mixture is subject to the treatment with methylation-sensitive nuclease (HpaII) or a control nuclease (HindIII-HF). Subsequently, the digested DNA mixture is subjected to PCR amplification using the respective FAM-labeled primers (HindIII-HF reaction) or HEX-labeled primers (HpaII reaction). The PCR products are then pooled and analyzed by capillary electrophoresis.
Both digestion control and GC reference standard migrate in the early window of the eletropherogram and do not interfere with the sample-specific profile. The loss of the amplicons from digestion control in the HEX-labeled PCR indicates the efficiency of the HpaII digestion. The GC reference standard is used to normalize signal intensity between the FAM- and HEX-labeled PCR products. Addition of GC reference standard prior to restriction enzyme digestion is used to normalize the variability of the amount of genomic DNA in each reaction. Therefore, the percentage of methylation by each allele is determined as a ratio of peak height between the digested (HEX) and control reaction (FAM) after normalization to the GC reference standard from the corresponding reaction.

Example 10

mPCR Assessment of Cell Line DNA in the Alternative Workflow and Comparisons with SB Analysis

mPCR according to the alternative workflow of Example 9 was evaluated with 4 commercially available cell line DNA templates (Coriell Institute for Medical Research) that included normal, premutation, and full mutation alleles from both male and female samples. Each sample was premixed with digestion control comprising SEQ ID NO: 50 and GC reference standard in which the A, B, and C sequences comprised SEQ ID NOs 17, 48, and 39, respectively. After addition of the digestion control and GC reference standard, the sample was divided into two portions. One portion of the sample was subjected to HpaII digestion, while the other was subjected to HindIII-HF digestion as a control reaction. 25-27 cycles of PCR amplification was then performed with each of the two portions using labeled primers as in Example 9, and products were resolved by CE. DNA from the same cell lines was also analyzed by SB. Results for allele size and methylation status from mPCR and SB are summarized in Table 9. Electropherograms of the 4 samples with corresponding SB data are shown in FIGS. 11A-11D. In each figure, the top panel shows the portion of the sample treated with HindIII-HF as control, and the bottom panel reveals the same sample digested with HpaII. Each figure also includes the methylation percentage determined by mPCR.
For each sample, the mPCR results were consistently in agreement with the SB data. For example, the two male full mutation samples (NA07862 and NA06852) were measured as having ≧100% methylation by mPCR, consistent with the presence of product only in the methylated region for the allele >200CGG in the SB.
In addition, mPCR provided more detailed information for allele-specific methylation status in samples with complex mosaicism. For example, two mosaic female samples (NA06896, 23/96-140 and NA20242, 30/73) were detected with primary peaks on SB, but these samples also revealed low abundant peaks not visualized on SB (FIGS. 11C-11D) when analyzed by mPCR. The mPCR data also revealed the individual contribution of each allele to the methylation pattern on SB. For example, NA06896 was detected with fully methylated 113 CGG & 138 CGG alleles, and unmethylated larger alleles of 143 to >200CGG (FIG. 11C), which is consistent with partial methylated FM reported in SB.

TABLE 9

Comparison of mPCR and SB analysis for 4 cell line DNA samples. All samples giving
measurements of 100% or greater methylation were categorically scored as “≧100%”.

Sample information

Coriell

SB Analysis

mPCR

			Catalog		Categorical	%
			Repeat	Estimated	Methylation	Digestion	mPCR
Sample			Length	Size	(Full, Partial	of Dig	Repeat	Methylation
ID	Genotype	Sex	(CGG)	(CGG)	or Non)	Ctrl.	Length	% on mPCR

NA07862	FM	M	Full	501-550	Full	98%	>200	≧100%
NA06852	FM	M	Full	660-990	Full	99%	>200	≧100%
NA06896	FM	F		23/95-140	Normal	Partial	98%	23	35%
				148-201	Partial		113	92%
							138	≧100%
							154	4%
							199	5%
							>200	12%
NA20242	PM	F		30/73	30	Non	99%	30	11%
				73	Partial		73	72%
							97	12%
							104	≧100%

Example 11

mPCR Assessment with Clinical DNA Specimens in the Alternative Workflow

The mPCR assay according to the alternative workflow according to Example 9 was further evaluated with a set to 12 clinical specimens that represented a range of clinically relevant allele sizes and methylation status. Experiments were performed as described in Example 10. Results for allele size and methylation status from mPCR and comparison to SB are summarized in Table 10. Electropherograms of the samples marked with * in Table 10 are provided in FIG. 12A-12G with corresponding SB data.
mPCR results were in good concordance with SB analysis. mPCR provided higher resolution and allowed for more detailed detection and interpretation of different methylation states than SB. Some alleles unresolved by SB were easily distinguished by mPCR (such as two alleles of similar size). For example, sample #7 contains 30 and 31 CGG alleles, which were not distinguishable by SB. In mPCR, these two alleles were clearly detected with methylated 30 CGG and unmethylated 31 CGG (FIG. 12F), thus revealing allele-specific methylation not detectable by SB analysis.

TABLE 10

Comparison of mPCR and SB analysis for 14 clinical samples. Samples
marked with * are shown in FIG. 2. All samples with 100% or greater
methylation were categorically scored as “≧100%”.

mPCR

%

SB Analysis

Sample	Diges-		Methyl-	Categorical	Estimated
Information	tion of	mPCR	ation	Methylation	Methyl-

Sample	Sample	Dig	Repeat	% on	(Full, Partial	ation
ID	Call	Ctrl.	Length	mPCR	or Non)	by SB

#

1*	FM	99%	80	3%	Non		0%
			225	≧100%	Full	90%
			249	≧100%
			256	85%
			268	73%
			271	54%
#2*	FM	99%	94	7%	ND	ND
			209	≧100%	Partial	60%
			257	0%
			272	1%
#3*	FM	99%	240	90%	Partial	70%
			257	72%
			272	31%
#4*	PM	99%	23	28%	Partial	30%
			72	77%	Partial	60%
#5*	PM	99%	41	7%	Non		10%
			96	≧100%	Full	90%
			101	≧100%
			114	≧100%
#6*	Nor	99%	30	76%	Partial	50%
			31	9%
#7*	FM	99%	23	19%	Partial	30%
			94	3%
			239	98%	Full	100%
			257	90%
			271	96%

#8	PM	100%	155	≧100%	N/A
			175	2%
#9	PM	99%	41	43%
			57	16%
#10	FM	99%	53	0%
			153	96%
			256	1%
			271	1%
#11	FM	99%	198	74%
			213	84%
			257	63%
			272	≧100%
#12	FM	98%	149	19%
			258	≧100%
			268	≧100%
			273	≧100%

Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims. The listing of steps in a method in a particular order is not to be construed as an indication that the steps must be performed in that order, except where there is an explicit indication to the contrary or the result of one step is required for occurrence of another step. For example, steps of “contacting a first portion of the sample with a methylation-sensitive DNase” and “adding a GC reference standard to the sample” may be performed in any order because neither step requires a result from the other. On the other hand, “subjecting the first portion and a second portion of the sample, each containing the GC reference standard, to a DNA amplification reaction” occurs after “adding a GC reference standard to the sample” because the subjecting step requires the presence of the GC reference in portions of the sample, which results from the adding step.
All references cited herein are incorporated herein by reference in their entirety. To the extent publications and patents or patent applications incorporated by reference contradict the invention contained in the specification, the specification will supersede any contradictory material.

Claims

1. A method of characterizing a FMR locus in a DNA sample comprising the steps of:

a) contacting a first portion of the sample with a methylation-sensitive DNase;

b) adding a GC reference standard to the sample, wherein the reference standard has at least 75% GC-richness;

c) subjecting the first portion and a second portion of the sample, each containing the GC reference standard, to a DNA amplification reaction, wherein the amplified DNA in each portion is labeled with a different label; and

d) analyzing the amplified DNA from the first and the second portion of the sample, thereby characterizing the methylation status of the FMR locus.

2. The method of claim 1, wherein step (d) comprises capillary electrophoresis (CE).

3. The method of claim 2, wherein the GC reference standard is devoid of recognition sites for the methylation-sensitive DNase.

4. The method of claim 2, wherein the amplified DNA from the first and the second portion are analyzed in a single CE run.

5. The method of claim 2, wherein the GC reference standard has a CE migration time that does not overlap with a naturally occurring FMR allele.

6. The method of claim 2, wherein the GC reference standard has a relative retention time of less than about 20, about 24 to 27, or greater than about 32 CGG repeats.

7. The method of claim 2, wherein the GC reference standard has a relative retention time of less than about 3 CGG repeats.

8. The method of claim 2, where in the GC reference standard has a relative retention time of about 175 to about 225 CGG repeats.

9. The method of claim 1, wherein the methylation-sensitive DNase is chosen from Hpa II, Eag I, or Nru I.

10. The method of claim 1, wherein the amplification reaction is capable of amplifying at least 200 CGG repeats.

11. The method of claim 10, wherein the amplification reaction comprises a dNTP mixture with a GC/AT ratio greater than 1.

12. The method of claim 11, wherein the GC/AT ratio is from about 2.5 to about 10.

13. The method of claim 1, wherein the FMR locus is a FMR1 locus.

14. The method of claim 1, wherein the GC reference standard is added to the sample after contacting the first portion with the DNase.

15. The method of claim 1, wherein the GC reference standard is added to the sample before contacting the first portion with the DNase.

16. The method of claim 1, further comprising contacting the second portion of the sample with a control enzyme.

17. The method of claim 16, wherein the control enzyme is chosen from EcoRI and Sau3A1.

18. The method of claim 16, wherein the GC reference standard is added to the sample before contacting the first portion with the DNase and the control enzyme is chosen from HindIII-HF, EcoRI, DpnI, and NaeI.

19. The method of claim 1, further comprising adding a digestion control to the sample before contacting the first portion of the sample with the methylation-sensitive DNase.

20. The method of claim 19, wherein the digestion control has a relative retention time of less than about 3 CGG repeats, the GC reference standard has a relative retention time of less than about 3 CGG repeats, and the relative retention times of the digestion control amplification product and the reference standard differ by about 4 CGG repeats or more.

21. A method of analyzing a human DNA sample comprising the steps of:

a) contacting a first portion of the sample with a methylation-sensitive DNase;

c) subjecting the first portion and a second portion of the sample to a DNA amplification reaction, wherein the amplified DNA in each portion is labeled with a different label; and

d) analyzing the amplified DNA from the first and the second portion of the sample, thereby detecting a genotype associated with Fragile X Syndrome, Fragile X-associated tremor ataxia syndrome, and/or Fragile X-associated primary ovarian insufficiency.

22. A GC reference standard comprising a nucleic acid sequence of the formula:

5′-A-B-C-3′

wherein

A is a sequence comprising at least 10 consecutive nucleotides of SEQ ID NO: 40 wherein A is capable of specifically hybridizing to a genomic FMR1 5′ untranslated region;

C is a sequence comprising at least 10 consecutive nucleotides of SEQ ID NO: 41 wherein C is capable of specifically hybridizing to a genomic FMR1 5′ untranslated region; and

B is a sequence having at least 75% GC-richness, and is between X−300 and X+10 nucleotides in length, wherein X is the sum of

a) the number of nucleotides between the 3′ end of A and the last nucleotide of SEQ ID NO: 40; and

b) the number of nucleotides from the first nucleotide of SEQ ID NO: 41 to the 5′ end of C.

23. The GC reference standard of claim 22, wherein B is between 150 and 200 nucleotides in length.

24. The GC reference standard of claim 23, wherein B has at least 90% GC-richness.

25. The GC reference standard of claim 23, wherein B has at least 94% GC-richness.

26. The GC reference standard of claim 22, wherein A comprises GCGCTCAGCTCCGTTTCGGT (SEQ ID NO: 17).

27. The GC reference standard of claim 22, wherein C comprises AGTGCGGGGCTCCAATGGCG (SEQ ID NO: 39).

28. The GC reference standard of claim 22, wherein B comprises at least 100 nucleotides of SEQ ID NO: 48 or at least 100 nucleotides of SEQ ID NO: 49.